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ABSTRACT 
The Role of Obesity, Diabetes, and Hypertension in Cleft Lip 
and Cleft Palate Birth Defects 
by 
Hebah A. Kutbi, Doctor of Philosophy 
Utah State University, 2014 
 
Major Professor: Dr. Ronald Munger  
Department: Nutrition, Dietetics, and Food Sciences 
Orofacial clefts (OFCs) are among the most common structural birth defects 
and a public health problem. Several studies suggest that maternal obesity pre-
existing diabetes mellitus (DM), and the underlying metabolic abnormalities, may be 
involved in the pathogenesis of cleft lip (CL) and cleft palate (CP) birth defects. 
Although hypertension and gestational diabetes mellitus (GDM) have been associated 
in a few studies with congenital birth defects, studies examining the risk associated 
with OFCs are limited. The overall objective of this dissertation was to examine the 
association between maternal obesity, DM, GDM, and hypertension and the risk of 
OFCs in case-control studies.  
Analyses of data from an international consortium revealed that maternal 
obesity (pre-pregnancy BMI >30), compared to normal weight (18.5<BMI>25), was 
associated with an increased risk of cleft palate with or without cleft lip (CP/L) 
(adjusted odds ratio (aOR) =1.13 [95% confidence intervals (CI) 1.01-1.25]). We also 
found a marginal association between maternal underweight and CP/L (1.0 
[reference]; aOR=1.14 [0.97-1.34]. CL only was not associated with maternal 
bodyweight. Interestingly, among college-graduates, there was no increased risk of 
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CP, but mothers with less than a completed college education had an increased risk of 
CP for underweight and obesity.  
Investigation of the Utah OFC data provided evidence that maternal 
GDM is significantly associated with isolated (aOR=2.63 [1.30-5.34]) and non-
isolated clefts (aOR=2.66 [1.02-6.97]). Maternal hypertension is significantly 
associated with non-isolated clefts (aOR=6.56 [2.18-19.77]). We found a further 
elevated risk of OFCs among GDM mothers and those with hypertension who were 
also obese.  
The analyses of data from an international consortium revealed significant 
associations between maternal diabetes and the risk of OFCs. The estimated relative 
risk of DM for isolated OFCs was 1.33 [1.14-1.54] and was slightly higher for 
multiple OFCs (aOR=1.86 [1.44-2.40]). Diabetic mothers with abnormal body-mass-
index had an increased risk for having inborn with OFCs.  
 Throughout the dissertation, we demonstrated the extent in which maternal 
obesity, pre-existing DM, GDM, and maternal hypertension may increase the risk of 
OFC birth defects. The results highlight the need for pre-conceptional program 
planning for the prevention of OFCs with screening for abnormal glucose tolerance 
and hypertension.  
(157 pages) 
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PUBLIC ABSTRACT 
The Role of Obesity, Diabetes, and Hypertension in Cleft Lip and 
Cleft Palate Birth Defects 
Hebah Kutbi 
Orofacial clefts (OFCs) are birth defects characterized by immediately 
recognizable disruption of normal facial structure caused by abnormal facial 
development during the first six to eight weeks of gestation, causing a cleft in the lip 
or the palate. OFCs are among the most common structural birth defects and a public 
health problem. Some studies have found that maternal obesity, diabetes, 
hypertension, or the underlying metabolic abnormalities known as the metabolic 
syndrome, might be associated with the risk of OFCs, though other studies have been 
inconsistent. Data of mothers who have had children with OFCs were compared to 
those of children without OFCs to assess the association between maternal obesity, 
diabetes or gestational diabetes, or hypertension and the risk of OFCs.  
Results of studies conducted in this dissertation indicated an increased risk of 
OFCs when abnormal maternal weight is present. Both maternal obesity and 
underweight were found to be associated with increased risk of having children with 
orofacial clefts. This effect however was only present among mothers with lower 
maternal education levels. Maternal diabetes mellitus and gestational diabetes 
increased the risk for having a child with OFC birth defects, as well as maternal 
hypertension. When maternal diabetes or hypertension was combined with obesity or 
underweight, the risk of OFC increased compared to normal weight mothers.  
With the increased prevalence of obesity, diabetes, and hypertension and the 
association of these syndromes with OFCs, it is recommended that mothers planning 
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to become pregnant to follow healthy habits, maintain healthy weight, and be 
screened for possible diabetes or hypertension prior to conception and early in 
pregnancy. 
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Each year an estimated 150,000 babies are born with birth defects in the 
United States 1. According to a 1998 report of the National Center for Health 
Statistics, birth defects cause one in five infant deaths, making them the leading cause 
of infant mortality 1. The National Vital Statistics Report indicated that in 2010, infant 
mortality rate due to congenital malformations was 127.7 per 100,000 live births, 
accounting for 20.8% (n=5,107) of total infant deaths 2. Clefts of the lip and palate, 
collectively termed orofacial clefts (OFCs), are among the most common structural 
birth defects and are therefore a public health problem 3, 4. Between 1998 and 2001, 
the Centers for Disease Control and Prevention (CDC) reported that 6,800 infants in 
the United States were affected by OFCs annually 5. In 2010, an estimated 4,437 live 
births per year had cleft lip or cleft palate 6. Several studies suggest that maternal 
obesity, diabetes, or the underlying metabolic abnormalities known as Metabolic 
Syndrome, may be involved in the pathogenesis of cleft lip and cleft palate 7-9. Yet, 
further studies are needed for a more complete understanding of the etiology of this 
disorder 10. 
 Obesity is defined as having a body-mass-index (BMI; weight in kg/height in 
M2) of ≥30.0. Among adults, age-adjusted prevalence of obesity in 2007-2008 was 
33.8%, with an overall 32.2% among men and 35.5% among women 11. However, it 
was expected that by 2015, 41% of adults in the United States would be obese 12. 
Increased adiposity is associated with an increased incidence of a number of 
conditions, including diabetes mellitus (DM) 13 and hypertension 14. An increased risk 
for DM begins to rise at a BMI of  >30 13, whereas BMI above the normal range is 
associated with a number of adverse reproductive health outcomes, including
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gestational diabetes mellitus (GDM) 15, pregnancy induced hypertension 16, and birth 
defects 17. 
Maternal DM before pregnancy (pre-gestational diabetes) has been associated 
with congenital malformations, including OFCs, in the offspring. Poor glycemic 
control in very early pregnancy may increase the malformations rate 18. However, pre-
pregnancy care of mothers with existing diabetes may reduce the malformation risk 
19. There is less evidence on the teratogenic risk of GDM, although this disorder has 
been suggested to be a human teratogenic factor 20. In 1985, congenital malformations 
represented the largest single cause of mortality in infants of diabetic mothers 21. 
Schaeffer et al. studied 3743 pregnancies diagnosed with GDM and found an 
association between maternal blood glucose levels and the risk for major–but not 
minor–congenital malformations in the offspring. Women with GDM were identified 
in a screening program while birth defects were identified by intense pediatric 
examinations at the time of discharge from the delivery unit 22.   
 Metabolic syndrome is a cluster of metabolic and physical characteristics that 
raise the risk of developing heart disease, diabetes, and other diseases. These include 
insulin resistance, hypertension, obesity, central body fat deposition, low HDL 
cholesterol, and hypertriglyceridemia 23. In 2009, approximately 34% of adults met 
the criteria for metabolic syndrome and its prevalence increases with age and BMI 24. 
Hypertension, which complicates approximately 10% of all pregnancies, 
remains a major cause of morbidity and mortality for both mother and fetus 25. Blood 
pressure normally decreases early in pregnancy, and by the mid-trimester, diastolic 
levels are often 10 mmHg lower than postpartum measurements. Pressures then 
increase gradually, approaching pre-pregnant levels near term, and some have even 
recorded transient rises in the immediate puerperium 26. Because cardiac output is 
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also elevated, the decrease in blood pressure is primarily related to a marked decrease 
in peripheral vascular resistance 25. Infants born to women who have hypertension 
early in pregnancy have an increased risk of birth defects. In 2011, researchers at the 
Kaiser Foundation Research Institute in California collected health information on 
465,000 mother-infant pairs in the Kaiser Permanente Northern California health care 
system and compared the risk of birth defects in infants born to mothers with 
hypertension using antihypertensive drugs to that of infants born to mothers with 
hypertension but not taking any antihypertensive drugs. Results indicated an 
increased risk of major non-chromosomal congenital malformations in all mothers 
with hypertension and the risk remained elevated even with the use of hypertensive 
drugs during pregnancy 27. 
Maternal diabetes, or the underlying metabolic abnormalities known as the 
metabolic syndrome, was hypothesized to be involved in the pathogenesis of cleft lip 
and cleft palate, while it was debated whether this is true also at maternal GDM. With 
the rising rates of excess weight among pregnant women, even a modest effect of 
maternal obesity may result in an increased population burden of OFC. Maternal 
weight gain increases the risk for DM and hypertension. Although hypertension has 
been associated in a few studies with congenital birth defects, studies examining the 
risk associated with OFC are limited. Given the aforementioned information, this 
dissertation is a step towards a comprehensive analyses of the effect of maternal 
obesity, diabetes, GDM, and hypertension on the risk of OFC birth defects. Further 
analyses were performed to describe possible potential confounders that may interact 
with these risk factors. The work outlined in chapters one through six can be useful in 
determining the associations between maternal obesity, diabetes, GDM, and 
hypertension on the risk of OFC birth defects.  
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Dissertation Hypotheses and Objectives 
The overall objective of this dissertation was to examine the associations between 
maternal obesity, diabetes, and hypertension and the risk of orofacial clefts. The 
specific objectives and hypotheses of this dissertation are:  
1. To determine whether maternal obesity is associated with the risk of cleft lip and 
cleft palate. Maternal obesity is hypothesized to cause cleft lip and cleft palate via 
metabolic abnormalities that affect fetal development. This hypothesis was 
examined in analyses of data from a large international consortium of case-control 
studies from Utah, Iowa, Norway, Denmark, and the U.S. National Birth Defects 
Prevention Study. 
2. To investigate whether maternal gestational diabetes and hypertension are 
associated with risk of cleft lip and cleft palate. These two factors are 
hypothesized to cause cleft lip and cleft palate via metabolic abnormalities that 
affect fetal development. This set of related hypotheses was examined in analyses 
of data from the Utah case-control cleft study. 
3. To examine the association between maternal diabetes and the risk of cleft lip and 
cleft palate. This hypothesis was examined in analyses of data from the 
international consortium of case-control studies from Utah, Iowa, Norway, 
Denmark, and the U.S. National Birth Defects Prevention Study. 
Dissertation Structure 
This dissertation is divided into six chapters. 
Chapter 1 provides an introduction to the research along with outlines 
covering study objectives and hypotheses. 
Chapter 2 is titled “Obesity, Diabetes, and Hypertension and Cleft Lip and 
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Cleft Palate Birth Defects: A Review.” This chapter provides literature review of each 
of these three modifiers and evidence that they are related to the risk of orofacial 
clefts. 
 Chapter 3 is titled “Maternal Obesity and Underweight and the Risk of 
Orofacial Clefts.” Chapter 3 undertakes analyses of data from an international 
consortium, including case-control studies from the U.S and Norway, to test whether 
an association between maternal obesity and underweight and the risk of OFCs exist 
after adjusting for potential confounders. The demographic characteristics for each 
study site were explored. The risk of maternal body weight groups on OFC subtypes 
(cleft lip only (CLO), cleft lip with or without cleft palate (CL/P), and cleft palate 
with or without cleft lip (CP/L)) was tested among each study site. The association 
between maternal education levels and the risk of each OFC subtype (CLO, CLP, 
cleft palate only (CPO), CP/L, and all cleft subtypes) was also tested. Given the 
known association between maternal education level and risk of orofacial clefts, the 
risk of maternal body weight groups stratified by maternal education levels was 
examined.  
Chapter 4 is titled “The Role of Gestational Diabetes Mellitus and 
Hypertension on the Risk of Orofacial Clefts in Utah.” This chapter describes the 
main characteristics of the Utah population sample and examines the independent 
effect of maternal GDM and hypertension on the risk of cleft. Given that maternal 
obesity is a risk factor for OFC, the effect of maternal GDM and hypertension is 
assessed after stratifying data for maternal weight categories. 
Chapter 5 is titled “The Association Between Maternal Diabetes and 
Orofacial Clefts in an International Consortium of Case-Control Studies.” This 
chapter examines the association between maternal diabetes and each type of OFC 
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(isolated, multiple, and isolated and multiple clefts combined), and subtype (CLO, 
CL/P, CPO, and all clefts) using data from an international consortium that includes 
case-control studies from the U.S., Norway, and Denmark. The risk of maternal 
diabetes was also tested within each maternal body weight category and obesity 
levels. 
Chapter 6 wraps up with a discussion on the findings and provides 
conclusions and recommendation for further research directions and for practitioners. 
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CHAPTER 2 
OBESITY, DIABETES, AND HYPERTENSION AND CLEFT LIP 
AND CLEFT PALATE BIRTH DEFECTS: A REVIEW 
Birth Defects 
 Birth defects remain an important public health issue and the leading cause of 
infant mortality and disabilities in the United States. The National Vital Statistics 
Report indicated that in 2010, infant mortality rate due to congenital malformations 
was 127.7 per 100,000 live births, accounting for 20.8% (n=5,107) of total infant 
deaths 1. Children who survive and live with birth defects are faced with an increased 
risk of developing life-long physical, cognitive, and social challenges concerning 
which medical intervention and other supportive services have little impact 2. Parental 
consanguineous marriages, advanced maternal age, maternal smoking, poverty, poor 
nutrition, or alcohol and drug use are some of the risk factors that have been reported 
to cause birth defects 3. The National Birth Defects Prevention Network (NBDPN) 
provided an update of the national estimates of 21 selected birth defects. 
Chromosomal anomalies were the most common birth defects, with a prevalence of 
17.48 per 10,000 live births and accounting for 14.47 for Down syndrome, followed 
by orofacial defects, cardiovascular, musculoskeletal, gastrointestinal, and central 
nervous system defects, with prevalences of 16.98, 14.73, 14.13, 6.85, and 6.38 per 
10,000 live births, respectively 4.   
  The Metropolitan Atlanta Congenital Defects Program (MACDP), a 
population-based, active birth defects surveillance system operating in the five central 
counties of metropolitan Atlanta, examined the prevalence of birth defects among 
racial and ethnic subpopulations. Compared to births of non-Hispanic white women, 
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births to non-Hispanic black women had a significantly higher prevalence of five 
birth defects and a lower prevalence of 10 birth defects, while births to Hispanic 
women had a higher prevalence of four birth defects and a lower prevalence of six 
birth defects. However, the reasons for racial and ethnic variations in the prevalence 
of birth defects are not well understood 5. Disparities in the prevalence of birth defects 
may result from different underlying etiologies 5.  Some birth defects are inherited, 
while others are a product of harmful environmental factors or multifactorial, 
resulting from a complex interaction of genetic and environmental influences. 
Nevertheless, in about 50% of all birth defect cases, the causes remain unknown 6, 7. 
 Many birth defects occur due to abnormalities of the genetic material before 
the conception 7. For instance, the chromosomal abnormalities, which are changes in 
the number or structure of chromosomes and result in a gain or loss of genetic 
material, account for approximately 6.0% of birth defects in industrialized countries 8. 
Down syndrome, caused by an extra chromosome 21 (trisomy 21), is the most 
common chromosomal abnormality 7; single gene defects that are caused by 
alterations in gene structure (mutations) result in abnormal cell functioning and 
accounts for 7.5% of birth defects; and multifactorial disorders, alternately called 
congenital malformations, caused by the interaction of genes and the environment 
compose 20-30% of all causes of birth defects. However, birth defects originating 
after conception are largely non-genetic in origin. Intrauterine environmental factors, 
such as congenital infections, maternal illness and altered maternal metabolism as 
well as recreational and therapeutic drugs may cause the birth defects through the 
process of interfering with the normal growth and development of the embryo and 
deforming the fetus 7. Those birth defects compose 5-10% of the causes. Examples of 
these three categories include rubella and toxoplasmosis, maternal insulin-dependent 
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diabetes mellitus and iodine deficiency, and alcohol and antiepileptic drugs, 
respectively. Unknown causes lead to 50% of the birth defects 7. 
 Birth defects are multifactorial occurring due to a combination of genes that 
place the fetus at risk in the presence of specific environmental factors. A few 
examples are congenital heart disease, neural tube defects, and OFCs. Multifactorial 
inheritance can also be the cause of the many common systemic diseases with a 
genetic predisposition presenting later in life. Examples are hypertension, diabetes, 
stroke, mental disorders, and cancer 9.  
Cleft Lip and Cleft Palate Birth Defects 
 Orofacial clefts (OFCs) are congenital malformations characterized by 
immediately recognizable disruption of normal facial structure caused by abnormal 
facial development during the first six to eight weeks of gestation, causing a cleft—a 
gap. A cleft lip (CL) is a physical split or separation of one or both sides of the upper 
lip and appears as a narrow opening in the skin of the upper lip. This rupture often 
extends beyond the base of the nose and includes the alveolus, the bony structure of 
the maxilla containing the gums and dentition. A cleft palate (CP) is a split or gap in 
the palate, the roof of the mouth. A cleft palate can involve the hard palate (the bony 
front portion of the roof of the mouth), and/or the soft palate (the soft back portion of 
the roof of the mouth) 10.  
 It is important to distinguish between non-syndromic (isolated) and syndromic 
CL/P in order to determine management and recurrence risk for patients and families 
11. Non-syndromic OFCs, are those that occur with no other major anomaly or one or 
two minor anomalies 12 with an average prevalence of about 1/700 live births 13. 
Major anomalies usually include those of functional significance requiring some 
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degree of medical intervention. Minor anomalies, however, are those of minimal or 
no functional significance 14. CL can occur on one or both sides of the mouth. 
Because the lip and the palate develop separately, it is possible to have a CLO, a 
CPO, or both together 15. Thus, it is reasonable to limit the definition of non-
syndromic OFCs to those associated with no additional malformations and one or two 
minor anomalies. Affected individuals may have CL and CP (CLP), CP only (CPO), 
or CL only (CLO) 15.   
 There appears to be a greater chance of clefting in a newborn if a sibling, 
parent, or relative has had the defect. OFCs may cause complications in feeding, 
dental problems, and speech, hearing, and social integration. However, OFCs can be 
corrected to varying degrees by surgery, dental care, speech psychotherapy and 
psychosocial intervention 16.  
Epidemiology of Cleft Lip and Cleft Palate by Gender 
 Orofacial clefting is the most common craniofacial anomaly. Therefore, it is 
important to analyze the distribution of this defect and describe its characteristics 17. 
Using data from three registries of congenital anomalies based on a total of more than 
5 million births, some epidemiological characteristics were studied for 8,315 infants 
mainly with non-chromosomal CL/P. Robert et al. have observed a higher distribution 
of CL/P among males than females, while gender ratio was lower when multiple 
OFCs existed. The distribution of Pierre Robin type CP, which is a posterior U-
shaped CP, was similar among males and females, while other types of CP had the 
usual excess of females 18. Similarly, Mossey et al. have reported a higher frequency 
of CL/P among males than females, while isolated CP was more commonly observed 
among females 19. Gender ratio varied with severity of the cleft 19, presence of 
additional malformations, number of affected siblings in a family, ethnic origin, and 
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possibly paternal age 20. For instance, the gender ratio for CL/P in white populations 
was about 2:1 (male: female). The male predominance in CL/P became more apparent 
with increasing severity of cleft and less apparent when more than one sibling is 
affected in the family 21, 22. By contrast, the male excess in CL/P is smaller when the 
infant has malformations of other systems 20 
Epidemiology of Cleft Lip and Cleft Palate Birth Defects by the Geographical 
Variation 
The birth frequency of CLO, CLP, and CPO is not known in some parts of the 
world. Comparability of data related to the prevalence of OFCs among regions can be 
affected considerably by the differences in sample source (hospital vs population), 
duration, method of ascertainment, inclusion criteria, and sampling fluctuation 11. 
The United States 
Data from the California registry in the period 1983-1992 was used to estimate 
the prevalence of CL/P among Native Americans. The prevalence of CL/P was 
reported to be as high as 1.99 per 1000 births 23. The National Birth Defects 
Prevention Network (NBDPN) examined the prevalence of OFCs by U.S. state. The 
highest reported was for New Mexico in the period 1995-1996, with a prevalence of 
1.73 per 1000 live births and the stillbirths combined. In Wisconsin 1989-1995, the 
prevalence was 1.56 per 1000 live births and stillbirths combined. The lowest 
recorded prevalence rate for CL/P was 0.59 per 1000 live births in Alaska, for 1996 
only, and Illinois, for the period 1989-1996 11.  
Latin America 
The Latin American Collaborative Studies of Congenital Malformations 
reported the prevalence of CL/P across Central and South America. The highest CL/P 
prevalence recorded was for Bolivia (2.28 per 1000), followed by Argentina (1.16 per 
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1000) and Chile (1.13 per 1000). These are geographically in the southern parts of 
South America and are generally less developed than the U.S. and Canada 11. At the 
lowest end of the scale was the geographically different population in Central 
America and the Caribbean, reporting a prevalence of 0.42/1000, followed by 
Venezuela (0.77 per 1000) 24.  
Europe  
The highest prevalence of CL/P from all European countries was 1.46 25. 
Overall, the highest frequencies of CL/P were found in Norway, Denmark, Sweden, 
Iceland, and the northern Netherlands, while the lowest levels were in Southern 
Europe 11. In 2013, an epidemiological study conducted in Australia reported the 
prevalence of OFCs among the Australian populace. The birth prevalence of CL/P 
reported was 12.05 per 10,000 births (1 in 833 births). For CP, the prevalence was 
10.12 per 10,000 births or 1 in 990 births. CL/P rates were significantly higher in 
males than females; while for CP, the prevalence rate in females was significantly 
higher than for males. Compared with non-Aboriginal Australians, birth prevalence 
rates for Aboriginal Australians were 1.89 times higher for CL/P and 1.30 times 
higher for CP. Birth prevalence of all forms of OFC did not differ by geographic 
location or by socioeconomic status. From 1980 to 2009, there was no significant 
change in annual rates for CL/P but rates for CP increased by an average of 1.97% per 
year 26.  
The Middle East 
 In the Middle East, the highest record of CL/P was 1.89 per 1000 live births in 
a Saudi Arabian Hospital-based 27, followed by a reported non-syndromic prevalence 
of OFCs in Kuwait ) in the period 1985-1987 (1.06 per 1000 live births28. In Turkey, 
studies of OFCs are limited. However, it has been reported that 194 cases were 
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identified with an age range of 1 to 65 years. Among the cases, 127 subjects (65.5%) 
had isolated CP, including 63 females and 64 males; 42 (21.6%) subjects had CL, 
including 17 females and 25 males; and 25 subjects (12.9%) had CLP, including 12 
females and 13 males 29. 
The Far East 
The highest prevalence rate of OFCs in the Far East was reported from a 
hospital-based Japanese data between 1948-1954, revealing a prevalence of 2.13 per 
1000 live births 30. In the Philippines, a prevalence of 1.94 per 1000 live births was 
reported for OFCs in a 7-year survey of hospital records in the period 1989-1996 31, 
while in Taiwan, the prevalence of OFCs between 2002-2009 was 0.1% for CL/P and 
0.04% for CP 32.  
Environmental Risk Factors for Orofacial Clefts 
 Although the literature on OFCs is extensive, the exact etiology and the 
unique risk factors remain unknown 11. Several studies suggested a multifactorial 
etiology for OFC, with both genetic predisposition and environmental influence 
playing a role 11. A meta-analysis investigated the potential maternal factors 
associated with OFCs in the offspring. Data suggested that maternal socioeconomic 
status, smoking, alcohol consumption, medications, caffeine, and lead exposure are 
the most environmental risk factors associated with OFCs 33, 34, while folic acid intake 
by the mother was found to reduce the risk of CL/P in offspring in several studies 33, 
34. In a Case-Control Study of non-syndromic OFCs in Maryland conducted to 
examine both environmental and genetic risk factors for OFCs, and to test for possible 
interactions, researchers could not find a statistically significant association with any 
of the following: maternal smoking, vitamin use, urinary tract infection, or 
recreational drug use. This could be explained by the small sample size in the study 
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(n=171) 35. 
Socioeconomic status (SES) 
Several studies in the United States and other countries revealed possible 
associations between parental socioeconomic status and the risks for birth defects, 
including OFCs, though findings were inconsistent 36-39. For instance, a case-control 
study conducted in France between 1985 and 1989 reported an increased risk for 
OFCs among mothers with low SES measured by household income 40. The National 
Birth Defects Prevention Study (NBDPS), an ongoing case-control study of about 30 
different birth defects, started in 1997, examined individual and household SES in 
relation to phenotypes of selected birth defects, including OFCs, based on 2,551 
normal-formed live born controls and 1,841 cases delivered in 1997–2000. The 
individual SES was measured by parental education, occupation, and household 
income. Household SES index was defined by combining all individual SES 
measures. Elevated risk of CPO in the offspring of fathers with lower education levels 
and maternal operator/laborer occupation was observed 41. Mossey and colleagues 
(2003) conducted a population-based case-control study in Scotland to investigate the 
association between SES according to household income and OFCs. Results revealed 
a strong association between OFC and SES, with a stronger pattern for CL/P than for 
CPO 42. In a case-control study conducted in Philippines and included two separate 
sites, maternal lower education level was significantly associated with an increased 
risk of OFCs in Negros Occidental but not in Davao sample 43  
  In contrast, a population-based case-control study consisted of 696 case 
mothers and 734 control mothers found no significant effect of SES on increasing the 
risk for OFCs 39. Another population-based Hungarian case-control study included 
1,374 cases with CL/P, 601 with posterior CP, and 38,151 controls and found no 
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difference in SES status, measured by maternal employment, between mothers of 
these two types of OFC cases and controls 44. In Sweden, Kallen reported no 
association between low maternal education levels and the risk of OFCs 45. Different 
measures of SES and different prevalences of birth defects across geographic 
populations may have contributed to the inconsistent findings to some extent. 
Smoking 
Several studies investigating the association between maternal smoking and 
the risk of OFCs have found positive associations with dosage effects 46-49, while 
others had conflicting results 50-53. Population and sampling variations in addition to 
the variation in inherited pharmacogenetic susceptibilities may contribute to the 
disparities in cigarette smoking effects 54. For example, a meta-analysis that included 
data from 24 case-control and cohort studies found a statistically significant 
association between CL/P and maternal smoking. It was suggested that smoking 
during pregnancy would increase the risk of having a child with CL/P and CP by 30% 
and 20%, respectively 55. However, this association was significant for non-Hispanic 
Whites, but not for non-Hispanic Blacks and Hispanics 56. Maternal passive smoking 
has been also associated with increased risk of CL/P. A study conducted in Tehran, 
Iran found a positive association between the environmental tobacco smoke exposure 
and OFCs 57. Similarly, based on a study included 88 infants with CL/P and 651 
infants without any major external birth defects, the odds ratio for CL/P associated 
with maternal passive smoking was 1.8. After the adjustment for maternal occupation, 
periconceptional flu or fever, and infant gender, the risk increased to 2.0.  
 Since the mid-1990s a number of epidemiological studies have investigated 
interactions between various genes (transforming growth factor alpha (TGFa), 
transforming growth factor beta-3 (TGFb3), retinoic acid receptor alpha (RARA), 
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msh homeobox-1 (MSX1), cytochrome P (CYP), glutathione S-transferase (GST) and 
epoxide hydrolase-1 (EPHX1)) 58 and markers in the glutathione s-transferase-1 
(GSTT1) or nitric oxide synthase-3 (NOS3) gene 54, 59-61 and smoking by women 
during pregnancy in relation to the development of CL/P in their offspring 58. Case-
triads have suggested an association between a NAT2 haplotype and isolated CL but 
with little evidence of interaction with smoking, but the other genes related to 
detoxification of compounds of cigarette smoke (NAT2, CYP1A1, GSTP1, GSTT1, 
and GSTM1) were not confirmed 62. Smoking has also been recently associated with a 
joint risk with variants in IRF6, while the same study reported interactions between 
multivitamins (MVIs) and IRF6 variants 63. These findings have been inconsistent, 
suggesting that any interaction would probably explain only a small proportion of 
OFCs. Such studies are still preliminary 55. 
Alcohol consumption 
Several studies have shown an association between prenatal alcohol exposure 
and OFCs 64, 65, but the evidence has been more inconsistent 66. Studies also suggest 
that ‘binge’ drinking patterns increase the risk of OFCs 67, which is supported by 
associations with variation in the ADH1C alcohol dehydrogenase gene. However, 
these links to alcohol consumption remain to be confirmed 68.  
Maternal alcohol consumption was also examined in some studies in relation 
to OFC in the offspring. For example, Werler et al. explored the association between 
maternal alcohol use and the risk of birth defects in the offspring. Three measures of 
alcohol exposures were used: (1) maximum number of drinks in any day (maximum 
intensity), (2) average daily frequency, and (3) average intensity of drinking per day. 
The only statistically significant increased risk was observed among CL/P cases in the 
highest intake category, five or more drinks per day (odds ratio (OR)=3.0 [95% 
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confidence intervals (CI) 1.1-8.5]) 69.  
In a population-based case-control study conducted in Iowa between 1987 and 
1991, cases were obtained from the Iowa Birth Defects Registry. Alcohol use was 
categorized as 1-3, 4-10, or >10 drinks per month within the three months prior to 
conception. CL/P risk was significantly associated with increasing alcohol exposure 
64. Another population-based case-control study of California births from 1987 to 
1989, investigated the association between maternal alcohol use and the risk of OFCs. 
Data on alcohol use was categorized as never, 1-3 during the four months critical 
window period, 1-3 per month, 1-4 per week, or daily. The only significant 
associations were found among mothers reporting five or more drinks per drinking 
occasion, with ORs of 3.4 [95% CI 1.1-9.7] for isolated CL/P, 4.6 [95% CI 1.2-18.8] 
for multiple CL/P, and 6.9 [95% CI 1.9-28.6] for syndromic OFCs 70. Romitti and 
colleagues (1999) conducted a study in Iowa and found a significant increased risk for 
CL/P among mothers reporting >4 drinks per month during the periconceptional 
period 71. Yet, in a multicenter case-control study in four European countries where 
alcohol use was defined as <70grams or >70 grams per week found a statistical 
significant increased risk only for isolated and non-isolated CP. This finding was 
inconsistent with the studies listed above, which showed no significant association 
between maternal alcohol use and CP 65.  
Medications 
Inconsistent associations have been found when looking at OFCs and 
anticonvulsant seizure medications, corticosteroids, or benzodiazepines, the anti-
depressant drugs 72-75. Epileptic women are at increased risk of having offspring with 
OFCs 76-79. It was unclear whether the epilepsy or the drug therapy used to treat the 
epilepsy that account for the increased clefting in epileptic women 11. Several studies 
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reported the increased risk of congenital malformations, including OFCs, with the 
anticonvulsant use to treat the epilepsy 78, 80-82. Smith has reported that more than 80% 
of pregnant women exposed to trimethadion in utero as the only anticonvulsant 
medication during pregnancy have either been spontaneously aborted or malformed at 
birth. The most frequent major malformations reported were CL/P and cardiac defects 
83. Using data from a population-based case-control study, maternal epilepsy and 
anticonvulsant drug therapy were both associated with increased risk of non-
syndromic CLP, but not with CPO 84.  
Hashmi et al. used data from the NBDPS to evaluate the association of 
maternal report of febrile illnesses in early pregnancy and the risk of OFCs. Mothers 
reporting febrile illness during pregnancy were stratified by fever grade and 
antipyretic use. The dataset included 5821 controls, 1567 cases of CL/P and 835 cases 
of CPO. A modestly increased risk was observed for isolated CL/P. Stratification by 
fever grade (body temperature <101.58 or 101.58F) did not yield significant 
differences in risk. Risk estimates were higher among women who reported a fever 
but did not take antipyretics to control their fever, particularly for non-isolated 
compared with isolated OFCs. The authors suggested that adequate control of fever 
may diminish the deleterious effects of fever in cases of OFC 85.  
Corticosteroids are mainly used to treat asthma, lupus, and rheumatoid 
disorders. Several studies reported a significant association between maternal use of 
the corticosteroids during the first trimester of pregnancy and the risk of having 
offspring with CL/P 74, 86, 87. It was theorized that the steroids act directly on the fetus, 
resulting in the loss of amniotic fluids 88. It was also suggested that receptors of 
glucocorticoids are more common in palatal mesenchymal cells, affecting the palatal 
formation when corticosteroids are used in the first trimester of pregnancy 89, 90   
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Caffeine  
 Bille et al. examined the association between the maternal lifestyle factors 
during the first trimester and OFCs based on prospective data from the Danish 
National Birth Cohort. Information on risk factors including tea, coffee, and cola 
consumption was obtained during pregnancy for 192 mothers who gave birth to 
children with an OFC while 828 mothers were selected as controls. The investigators 
found no association with maternal coffee or cola drinking among the mothers of 
affected infants. However, they found associations, although insignificant, with 
maternal drinking of more than 11 colas per week as well as drinking five or more 
cups of tea per day during the first trimester of pregnancy 91.  
 Another population based case-control study evaluated the association 
between maternal consumption of coffee and caffeine from other types of beverages 
in early pregnancy and the risk of delivering an infant with an OFC. Coffee 
consumption during the first trimester was associated with an increased risk of CLP, 
but not CLO, in a dose dependent manner. However, no evidence was found for an 
association between other caffeinated beverages and the risk of CLP 92. Further, 
Collier and colleagues (2009) investigated whether an association between maternal 
intake of coffee, teas, sodas, chocolate, and medications containing caffeine in the 
year before pregnancy and the risk of having a child with CL/P and CPO. The only 
significant association was between Isolated CL/P and the use of medications 
containing at least 100 mg of caffeine per dose 93.  
Other environmental pollutants  
 A few epidemiological studies investigated the relationship between exposure 
to environmental lead and birth defects and yielded inconsistent results 94. No effect 
on prevalence at birth of major or minor anomalies has been noted in some studies, 
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while other investigations reported an association between lead exposure and birth 
defects 95. Vinceti et al. observed an excess risk of cardiovascular defects, OFCs, and 
musculoskeletal anomalies in the lead polluted area 96. Additional environmental 
exposures include some specific teratogens 66, 97 such as stress 98 and ionizing 
radiation 99-101. Nonetheless, the harmful effects of these factors are still inconsistent 
100. Studies of gene-environment interaction may provide the understanding required 
to explain such effects 58. However, the interaction between the studies of the 
environmental risks and genes related to clefting require large prospective cohort 
studies and access to genetic material to measure effects on clefting. Attempts at 
identifying susceptibility loci via family and case-control studies have proved 
inconsistency 102. Yet, this is a promising area of research that can be expected to 
expand 103, 104. Thus, identification of the environmental risk, particularly if they can 
be adapted with genetic modifiers, can be more flexible and provide the best short-
term opportunities to provide more insight into better understanding and prevention 58, 
100.  
Maternal Vitamin and Mineral Nutrition  
 Observational studies suggest a role for maternal nutrition in OFC, even 
though assessments of dietary intake or biochemical measures of nutritional status are 
demanding and often not available in many of the impoverished populations with the 
highest rates of OFCs 105. 
Folate and nutrients related to one-carbon metabolism.  
Case-control studies of folic acid-containing multivitamin (MVI) supplements 
106-109, maternal dietary folate intake 57, 107, 110-112, and red cell and plasma folate 43, 112-
114 are inconsistent. Bille et al. have found that supplementation use of folic acid with 
400-mcg daily during the entire first trimester would have an inverse association 
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with OFC 91. Furthermore, in a 2011 case-control study in Utah, even though there 
were no differences in MVI use during pregnancy, case-mothers had significantly 
lower plasma and red cell folate levels than did control mothers, and the mean 
differences in folate levels between cases and controls widened years after the 
affected pregnancy, suggesting that progressive disorder of folate metabolism may be 
more common in case mothers compared to control mothers 34. 
Smits and Hukkelhoven reported an increased risk of adverse birth outcome at 
both ends of the interpregnancy interval spectrum, and a lower risk between 12 and 
23 months. The authors hypothesized the increased risks associated with short 
interpregnancy intervals are partly attributable to maternal depletion of 
micronutrients, particularly folate 115. Pregnancy places a burden on maternal 
micronutrient reserves and, if a new conception occurs before these reserves are 
sufficiently restored, growth and development of the conceptus may be compromised. 
Pregnancies accomplished shortly after the preceding delivery, in addition, are more 
likely than others to be unintended 116, which decrease the probability of 
periconceptional folic acid supplements (or MVI) use. However, Villamor et al., 
Krapels et al. and Wyszynski et al. suggested the risk of OFCs to be dependent on 
periconceptional intake of folate and other micronutrients 111, 117, 118.     
Other specific nutrients 
Strong evidence suggests an association between OFCs and other nutritional 
factors, including vitamin A, riboflavin, folic acid, panthothenic acid, vitamin B12, 
vitamin B6, and zinc 111, 119, 120. Mothers of infants with CL/P have been reported to 
have higher mean serum homocysteine levels 113, 114, 121. Vitamin B-6 (pyridoxine and 
related compounds) is also a co-factor in homocysteine metabolism and reduces the 
occurrence of CL/P in animal studies 114. Biomarkers of poor vitamin B-6 status were 
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associated with an increased risk of CL/P in the Netherlands 113 and in the Philippines 
43.  
Zinc is important during pregnancy for the fetal development; and zinc 
deficiency causes CP and other malformations in animal studies 122. Mothers of 
children with CL/P in the Netherlands had lower erythrocyte zinc levels than control 
mothers. In Philippines, zinc deficiency is widespread, and higher maternal plasma 
zinc levels were associated inversely with the risk of CL/P 120. However, in a case-
control study in Utah, Munger et al. found no difference in plasma zinc levels 
between case and control mothers 123.  
 Iron intake during pregnancy was also found to decrease the risk for OFCs 57. 
Other nutrients that may be involved in the etiology of CL/P include vitamin B2 and 
vitamin A 101. Bille et al., however, found no effect for vitamin A, B6 or B12 on the 
occurrence of cleft 91. 
According to a meta-analysis conducted in 2008 112, maternal use of MVI 
supplements in early pregnancy may attenuate the birth prevalence of clefts by 25%. 
A potential interaction between maternal hyperthermia during pregnancy and MVI 
supplement use was indicated by two previous studies, suggesting that supplement 
use reduces the increased risk of CL/P associated with hyperthermia 124, 125. On the 
other hand, Czeizel et al. indicated that daily supplementation with MVI does not 
have the inverse effect on the risk of clefts 126. It is difficult to determine whether this 
reduction is due to the consumption of a specific nutrient or other healthy behaviors 
confounded these results 112.  
Additionally, several studies investigated whether the risk for birth defects 
associated with maternal diabetes is attenuated by use of multivitamin supplements 
during the periconceptional period. Mothers with diabetes were having an increased 
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risk of having offspring with selected birth defects. However, the effect appeared only 
within mothers who had diabetes but were not taking MVIs, suggesting that MVI use 
during the periconceptional period may reduce the risk for birth defects among 
offspring of mothers with diabetes 127, 128  
Maternal Obesity and Underweight  
Obesity is a health condition in which excess body fat has accumulated, 
leading to increased health problems such as heart disease and type 2 diabetes and 
reduced life expectancy 129. Several factors including higher food energy intake with 
reduced energy expenditure (sedentary life style) 130 and genetic susceptibility are 
involved in obesity. In addition, pregnancy, in itself, is considered a risk factor for 
obesity as the mother gain weight during pregnancy and become increasingly obese 
with the frequent pregnancies, increasing the risk of congenital malformation and 
stillbirth 131. Maternal underweight is associated with several adverse outcomes, 
including low birth weight, anemia, and an increased mortality rate 132. Nevertheless, 
it remains an understudied health problem 133. 
A study intended to estimate the overall prevalence of overweight and obesity 
in the world and in various regions in 2005 and to project the global burden in 2030. 
Overall, 23.2% of the world’s adult population in 2005 was overweight with a higher 
rate in men (24.0%) than women (22.4%). The overall prevalence of obesity in the 
world, yet, was lower (9.8%) with a higher rate in women (11.9%) than obese men 
(7.7%). The total number of overweight adults was projected to increase during the 
period 2005 to 2030 from 937 million to 1.35 billion, while the number of obese 
adults was expected to increase from 396 million to 537 million without adjusting for 
secular trends 134. In addition, the incidence of obesity in pregnancy has increased 
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over the past 2 decades; with nearly 50% of U.S. women aged 15-49 years classified 
as overweight or obese 135.   
Body-mass-index (BMI) is a screening tool calculated from an individual's 
weight and height and defines people as overweight (pre-obese) if their BMI is 
between 25 and 29.9 kg/m2, obese when it is greater than 30 kg/m2, and underweight 
when it is less than 18.5 kg/m2 136. The BMI was originally invented by Adolphe 
Quetelet in 1832, as the relation between body weight and mortality, particularly 
cardiac disease and diabetes, gradually became a medical concern following the 
Second World War, and thus, a quest for a reliable and practical index of relative 
weight began to be increasingly important. Quetelet proposed that in adults, in 
exploring various indices combining weight and height, normal body weight in 
kilograms was proportional to the square of the height in meters 137, 138. Ancel Keys 
(1904–2004) confirmed the validity of the Quetelet Index and named it the BMI 139. 
Since then, as evidence of the association of obesity with various diseases continues 
to increase, the BMI has been used as an expression to report the link of excess 
relative weight to morbidity and mortality. Even though the generalizability and 
applicability of the BMI and its cut-off points to other populations has been 
questioned and its sensitivity as a measure of excess fat queried, it remains a 
dependable value and the basis of much of the associations reported heretofore with 
obesity 140. 
Maternal obesity and DM have been hypothesized to act synergistically in the 
pathogenesis of craniofacial abnormalities 141-143, and both maternal obesity 143, 144 and 
underweight 145 have been found to be associated with CL/P, but these issues are still 
insufficiently studied in OFC research 105. 
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The prevalence of obesity is currently rising worldwide. The epidemic is 
especially pronounced in women of reproductive age 146. A study conducted in 2012 
aimed to estimate the prevalence of adult obesity from the 2009-2010 National Health 
and Nutrition Examination Survey (NHANES) and compare adult obesity and the 
distribution of BMI with data from 1999-2008. The age-adjusted prevalence of 
obesity was 35.5% among adult men and 35.8% among adult women. Obesity 
showed no significant increase among women overall through 1999-2010 (adjusted 
odds ratio aOR=1.01 [95% CI 1.00-1.03]), but increases were statistically significant 
for non-Hispanic black women and Mexican American women. Men presented a 
significant linear trend through the period 1999-2010. For both men and women, the 
most recent 2 years (2009-2010) did not differ significantly from the period 2003-
2008. The prevalence of obesity was 35.5% among males and 35.8% among females; 
and BMI trends were similar to trends in obesity 147. When the future prevalence and 
BMI distribution was projected for 2010 to 2030, it was estimated that if the trends 
continue, in only 15 years, 80% of all American adults would be overweight or obese 
148.  
Maternal undernutrition is highly prevalent in low-income and middle-income 
countries, resulting in significant increases in mortality and overall disease burden.  
 Undernutrition involves deficiencies of essential vitamins and minerals 
(micronutrients) as one form of malnutrition, with obesity or over-consumption of 
specific nutrients as another form 149 For instance, it has been reported that in many 
areas of India people suffer from an under-nutrition problem 150. Nevertheless, Garg 
et al. recommended immediate attention for the higher rate of obesity among Indian 
women. Between the periods 1998–1999 to 2005–2006, the prevalence of obesity 
increased by 24.52%. 23.7% of women aged between 40-49 years were reported to be 
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obese. 23.5% of the obese residents reside in cities and 30.5% of them are wealthy. 
Several life style factors, such as sedentary lifestyle and junk food habits contributed 
to the increased prevalence in India 150. Another study comparing the prevalence of 
obesity between men and women in Shahjahanpur City, India found the highest rate 
to be in women at age 41-50 years (41.2%) and men at age 61-70 years (37.0%) 151. 
A longitudinal prospective study conducted in 2011 has revealed that in 
comparison to normal weight pregnant women, obese pregnant women were at 
increased risk of gestational diabetes mellitus, pregnancy induced hypertension, pre-
eclampsia, and postpartum infection morbidities. These women were more prone to 
develop diabetes and chronic hypertension in the future as well 152.  
As the prevalence of obesity has risen in developed countries, overweight 
among pregnant women has become increasingly common 153. In the United States, 
the incidence of obesity among pregnant women ranges from 18.5% to 38.3%, 
according to the cohort studies and cutoff points used to define overweight 154, 155. In 
Sweden, the prevalence of obesity among pregnant women was 26.1% 156, 157, while 
in Netherlands and France, the prevalence reported to be 17% 158. Compared with 
normal weight, maternal overweight is related to a higher incidence of premature 
birth, congenital malformations, and infant mortality 158.  
Maternal Obesity and Underweight and Cleft Lip and Cleft Palate Birth Defects 
Maternal obesity is associated with an increased risk of several congenital 
birth defects. The association is most pronounced for neural tube defects 159-163, 
cardiac defects 141, 160, 162, 164, and orofacial cleft (OFC) defects 117, 141, 143, 162, 165-167. 
However, many studies of maternal obesity and OFC risk were limited by the small 
sample sizes. For instance, Waller et al. has investigated the association between 
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maternal obesity, overweight, and underweight with distinct types of structural birth 
defects. The results suggested a borderline increased risk of isolated cleft palate only 
(CPO) within obese mothers (n=86; adjusted odds ratio (aOR)=1.27 [95% confidence 
intervals (CI) 0.98-1.66]) and a significant increase in cleft lip with or without palate 
(CL/P) within underweight mothers (aOR= 1.35 [1.04-1.76]) 162. A recent a 
population-based case-control study conducted in Florida found obese women to 
experience increased odds of having a child with CL/P after controlling for maternal 
race, education, smoking, marital status, nativity, and maternal age (OR=1.25 [95% 
CI 1.05-1.48] and CP, OR=1.32 [1.07-1.62]). However, in this same study, the 
offspring of underweight mothers were not at a higher risk of OFCs 168. 
Obese women were also reported by other studies to have high incidences of 
birth injuries and congenital malformations particularly OFCs 152, 169. Mothers who 
were underweight were reported to have no significant increase or decrease in the risk 
for heart defects, hypospadias, omphalocele, or craniosynostosis birth defects, but did 
not have a significant increase in risk for CL/P (adjusted OR1.35 [95% CI 1.04-1.76]) 
162. 
In a study consisting of 1,049,582 infants born in Sweden from January 1, 
1995 through December 31, 2007, maternal overweight and obesity were associated 
with an increased risk OFCs and the risk was increasing with the increased degree of 
obesity 170. Another study conducted in Sweden consisted of 988,171 infants, where 
OFCs were divided into: isolated CPO, CLO, and CL/P. The subjects were also 
divided into isolated (without any other major malformation present) or non-isolated 
(with other major malformations). In the maternal underweight group, no change in 
the risk for an infant with cleft was observed. In the overweight group, the risk was 
above one for CPO, CLO, CLP, and all CLs as well as for isolated and non-isolated 
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defects separately. In the group of obese mothers, there was an overall increased risk 
for infants with OFCs. The increased risk was higher when the OFCs were associated 
with other major malformations than when they were isolated 171. 
In Saudi Arabia in 2012, a study aimed at detecting the predictors of isolated 
structural birth defects in live births. Out of 37,168 live births, isolated structural birth 
defects were found in 318 cases. Obesity was a significant predictor for increased 
facial defects (aOR=5.92 [95% CI 2.8–12.4]) 172.  
In contrast to the studies described, Oddy and collegues reported an 
insignificant increased risk of OFC associated with obesity (n=6; aOR=1.41 [0.85-
2.34]) 173. Stott-Miller et al. also evaluated the effect of maternal obesity in relation to 
the risk of non-syndromic orofacial clefting. Regardless of the type of cleft, obese 
women had a small, non-significant increase risk of isolated OFCs in their offspring 
compared with normal-body mass index women 174. 
Villamor and Cnattingius have examined the associations between change in 
pre-pregnancy BMI from the first to the second pregnancies, and the risk of adverse 
outcomes during the second pregnancy in a nationwide Swedish study of 151,025 
women who had their first two consecutive singleton births between 1992 and 2001. 
The results supported the causal relation between being overweight or obese and risks 
of adverse pregnancy outcomes. Additionally, they suggested that modest increases in 
BMI before pregnancy could result in perinatal complications, even if a woman does 
not become overweight 175. Similarly, Guelinckx reported a higher incidence of 
premature birth, congenital malformations, and infant mortality among mothers with 
increased BMI 153. Cedergren and Kallen have regarded the positive association 
between maternal obesity and OFCs risk to the undetected type-2-diabetes mellitus 
within obese mothers 171. 
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Maternal Diabetes 
 Diabetes mellitus (DM) is a group of metabolic diseases resulting from defects 
in insulin secretion, insulin action, or both and characterized by chronic 
hyperglycemia with disturbances of carbohydrate, fat and protein metabolism. Three 
main types of diabetes have been defined: type-1, type-2, and gestational diabetes 
mellitus (GDM) 176. Type-1 diabetes mellitus or insulin-dependent diabetes mellitus 
(IDDM) is partly inherited and then triggered by certain infections. It results from a 
T-cell mediated autoimmune destruction of the pancreatic beta cells in genetically 
predisposed individuals 177. Type-2 diabetes or non-insulin-dependent diabetes 
mellitus (NIDDM) is due primarily to lifestyle factors and genetics 178. Type-1 and -2 
are both conditions that usually cannot be reversed. Hence, adherence to healthy diet, 
exercise, and use of appropriate medications is very important to keep blood sugar 
levels as close to normal "euglycemia" and avoid diabetes complications 179.  
Gestational diabetes mellitus (GDM) is a condition in which women without 
previously diagnosed diabetes exhibit high blood glucose levels (particularly during 
third trimester of pregnancy) when their bodies do not secrete the adequate insulin 
required during pregnancy 180.  Yet, mothers with GDM are at high risk for having or 
developing diabetes after their pregnancy 181. There is a very close relationship 
between GDM and Type 2 diabetes; GDM is considered to be a transient unmasking 
of an underlying predisposition to Type 2 diabetes, induced by the metabolic changes 
of pregnancy 182 
Diagnoses of Diabetes 
According to the American Diabetes Association (ADA), an individual can be 
diagnosed with DM in any one of the four methods: (1) Glycosylated hemoglobin, or 
hemoglobin A1C, of ≥ 6.5%; (2) Fasting Plasma Glucose (FPG) of ≥ 126 mg/dL; (3) 
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two-hour plasma glucose of ≥ 200 mg/dL during an Oral Glucose Tolerance Test 
(OGTT); or (4) classic symptoms of hyperglycemia or hyperglycemic crisis 
(polydipsia, polyuria, and unexplained weight loss) accompanied by a random plasma 
glucose of ≥ 200 mg/dL. However, different diagnoses criteria of GDM have been 
identified 183. For instance, the World Health Organization (WHO) in 2006 has 
developed a different diagnostic criteria with lower glucose cut-off values for GDM 
than the ones reported by the ADA and demonstrated that GDM should be diagnosed 
at any time in pregnancy if one or more of the following criteria are met: (1) FPG of 
92 -125 mg/dl); (2) one-hour plasma glucose of 180 mg/dL following a 75g OGTT; or 
(3) 2-hour plasma glucose 153 -199 mg/dL following a 75g OGTT. These guidelines 
are based on the association of plasma glucose and adverse maternal and neonatal 
outcomes during pregnancy, at birth and immediately following it 184.  
Diabetes first onset during pregnancy was recognized and termed “GDM” in 
the 1950s 185. GDM was originally defined to identify pregnant women who are at a 
higher risk for developing Type-2 diabetes later in life. The diagnosis is now being 
used to predict many potential neonatal and maternal complications in pregnancy 186. 
The prevalence of GDM varies greatly from 1 to 16% depending on the population 
studied and the diagnostic criteria used 187. For several years, the diagnosis of GDM at 
the local hospitals was made by a 100-g oral glucose tolerance test (OGTT) using the 
ADA criteria based on the “selective screening,” which is a selective strategy to 
detect GDM among older or obese women 188. However, the 100-g glucose load 
caused vomiting in nearly 10% of the women undergoing the OGTT 189. Therefore, 
after the ADA endorsed the 75-g OGTT for the diagnosis of GDM, it was decided to 
screen all women not previously known to have diabetes using the 75-gram OGTT 
between 24 and 28 weeks of gestation and using diagnostic cut points of greater than 
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92 mg/dl for the fasting glucose test; greater than 180 mg/dl one hour after drinking 
the 75-gram glucose solution; and greater than 153 mg/dl two hours after drinking the 
glucose solution 183.  
Epidemiology of Diabetes 
Diabetes mellitus is one of the most common chronic diseases in nearly all 
countries, and continues to increase in numbers and significance, as changing 
lifestyles lead to reduced physical activity, and increased obesity 190. The current 
estimate of diabetes prevalence worldwide was reported by the World Health 
Organization (WHO) to be 171,000,000, while it is projected that in 2030, the 
prevalence will increase to 366,000,000 191. Compared to estimates reported by 
previous studies, the prevalence of diabetes worldwide is significantly increasing. In 
1995, one worldwide study has projected the number of people with diabetes in all 
countries of the world for three points in time, the years 1995, 2000, and 2025. The 
prevalence of diabetes in adults worldwide was expected to be 4.0% (135 million) in 
1995, with a higher prevalence within females than males with diabetes (73 vs. 62 
million). However, the prevalence of diabetes was expected to rise to 5.4% (300 
million) by the year 2025, showing a 35% increase in the worldwide prevalence of 
diabetes, with a somewhat reduced excess within females than males (159 vs. 141 
million) 192, 193. Another study projected that in 50 years the number of American with 
diagnosed diabetes will increase 165%, from 11 million in 2000 to 29 million in 2050 
with a higher prevalence in females than in males after the age of 64. This study 
predicted that 37% of the 18 million increase in 2025 would be due to changes in 
demographic composition, 27% due to population growth, and 36% are due to 
increasing prevalence rates 194. Another study projected an increase of diagnosed 
diabetes prevalence from 4.4% (12.0 million) in 2000 to 9.7% (39.0 million) in 2050 
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195. In 2011, a follow-up epidemiological study evaluated the current prevalence of 
NIDDM in Saudi Arabia. The age-adjusted prevalence of NIDDM was 31.6% with a 
significantly higher prevalence in men (34.7%) than in women (28.6%) 196. 
The frequency of GDM usually reflects the frequency of NIDDM in the 
underlying population 197, 198. Established risk factors for GDM include advanced 
maternal age, obesity, and family history of diabetes 180. Xiong et al. estimated the 
prevalence, risk factors, and maternal and infant outcomes of mothers with GDM in a 
retrospective cohort study, based on 111,563 pregnancies delivered between 1991 
through 1997 in 39 hospitals, in northern and central Alberta, Canada. The prevalence 
of GDM was 2.5%. Risk factors for GDM included age over 35 years, obesity, history 
of prior neonatal death, and prior cesarean section. Teenage mothers and women who 
consumed alcohol were less likely to have GDM. Mothers with GDM were at 
increased risk of presenting with pre-eclampsia, premature rupture of membranes, 
cesarean section, and preterm delivery. Infants born to mothers with GDM were at a 
higher risk of being large-for-gestational-age 199. 
Maternal Diabetes and Cleft Lip and Cleft Palate Birth Defects 
Animal Studies 
Abundant clinical evidence indicated that diabetic mothers are at a high risk of 
having malformed offspring 200, 201 and that congenital malformations contribute to 
the high neonatal loss among infants born to diabetic mothers 202. Watanabe and 
collegues conducted an experiment to study the teratogenic effects of alloxan diabetes 
upon the mouse embryo. CP was found to be induced in embryos of alloxan-diabetic 
females, with the type and frequency of deformities being dependent upon the timing 
of alloxan injection 203.  
Ejdesjo et al. investigated the influence of parental transgenerational genetics 
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and maternal metabolic state on fetal deformity in diabetic rat pregnancy. Rats from 
an inbred malformation-resistant (W) strain, and an inbred malformation-prone (L) 
strain, were cross-mated to produce two different F1 hybrids, WL and LW. Normal 
(N) and manifestly diabetic (MD) WL and LW females were mated with normal 
males of the same F1 generation to obtain WLWL and LWLW F2 hybrids. Maternal 
diabetes increased malformation and resorption rates in both F2 generations. MD-
WLWL offspring had higher resorption rate but a similar malformation rate compared 
with the MD-LWLW offspring. Such results imply a possible teratological 
mechanism in diabetic pregnancies that are influenced by maternal metabolism and 
parental strain epigenetics 204. In contrast, an experiment was conducted to investigate 
whether congenital malformations in offspring of alloxan-diabetic mice can be 
prevented by insulin injections of 80 mg per kg of bodyweight during pregnancy. In 
50 successful pregnancies treated with insulin, only one fetus (0.2%) of 472 was 
malformed with a cleft palate; in 50 successful pregnancies given alloxan alone, 14 
(28%) of mice had one or more malformed fetuses. Altogether, six of 437 fetuses had 
CP. The difference between the alloxan group and insulin treated group in the number 
of mothers having malformed fetuses, and in the number of malformed fetuses 
produced was statistically significant according to the chi-square test with a 
probability level of less than 0.01. However, no significant correlation was observed 
between the magnitude of hyperglycemia of mother mice and the frequency of fetuses 
with congenital malformations 205.   
Human Studies 
Diabetes Mellitus (DM) has been identified as independent risk factors for 
several birth defects, providing support for a mechanism that involves hyperglycemia 
and hyperinsulinemia in the development of malformations 206, 207. Mothers who 
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develop GDM later in pregnancy may have had undiagnosed type-2 DM and are 
susceptible to acquire DM later in life 208. However, it is debated whether this is true 
also at gestational diabetes 209.  
A population-based case-control study was conducted to investigate the 
association between maternal DM and the risk of OFCs in the offspring using the 
1996 National Center for Health Statistics United States Natality database. The 
sample consisted of 2,207 live births with CL/P and 4,414 randomly selected live 
births controls. Results indicated an increased risk for CL/P among diabetic mothers 
compared to non-diabetic mothers (adjusted odds ratio (aOR)=1.35 [95% confidence 
interval (CI) 1.00–1.82]) 210. In a retrospective cohort study consisted of 126 non-
syndromic cleft cases, the association between maternal diabetes mellitus and the risk 
of OFCs was evaluated. Results indicated a significant increased risk of isolated CP 
within diabetic mothers 211. CP has been also reported by Arteaga to have a higher 
frequency in congenital malformation than in the rest of malformed newborns of non-
diabetic mothers 212.  
Data from the National Birth Defects Prevention Study from 1997 to 2007 
were used to investigate the association between maternal Dietary Glycemic Index 
(DGI) and the risk of birth defects among non-diabetic women.  Among the 53 birth 
defects analyzed, high DGI was significantly associated with encephalocele and atrial 
septal defect. Using quartiles to categorize DGI, the authors identified associations 
with CLP and anorectal atresia/stenosis. The joint effect of high DGI and obesity 
provided evidence of a synergistic effect on the risk of selected birth defects. High 
DGI was associated with an increased risk of a number of birth defects. Obesity 
coupled with high DGI appeared to further increase the risk for some birth defects 213. 
Additionally, using dietary data collected in the Boston University Slone 
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Epidemiology Birth Defects Study, Yazdy et al. examined the effect of a high dietary 
glycemic index (dGI) or load (dGL) on the risk of birth defects. High DGL intakes 
were more common than controls for OFC case groups, but the Odds Ratio (OR) 
estimates were unstable due to small population size 214.  
In 2002, a study was conducted to investigate the frequency of hyperglycemia 
in pregnant women who were without health benefits and did not receive prenatal 
specialist care. Clinical characteristics of newborns show statistically significant 
increased risk of CLP in offspring whose mothers had inadequate prenatal care 
compared to of infants whose mothers had regular prenatal care, suggesting a 
necessity to start establishing new programs and ways of making health information 
available to women in primary care clinics to educate the general population and 
stress the importance of regular visits to a prenatal care specialist 215.  
Goldman et al. investigated whether arachidonic acid is involved in processes 
analogous to neural tube folding and fusion in diabetic mothers. This hypothesis was 
raised by the role of arachidonic acid in palatal elevation and fusion. The study 
suggested that the mechanism of mediating the teratogenic effect of an increased 
glucose concentration involves a functional deficiency of arachidonic acid at a critical 
stage of organogenesis 216.  
Furthermore, a Turkish congenital malformation survey revealed a 
significantly frequent incidence of CPO. Abnormal ultrasonographic findings and 
disorders such as DM and GDM were found to be valuable indicators for the presence 
of congenital malformations in the fetus 217. 
Janssen et al. investigated the association between GDM and the development 
of congenital malformations from a populations-based retrospective study. Data for 
births to mothers with established diabetes were also available. Newborns of mothers 
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with established diabetes were more likely to have a congenital malformation than 
newborns of non-diabetic mothers. On the other hand, there was only a slightly higher 
prevalence of congenital malformations among newborns of mothers with GDM. The 
association with maternal established diabetes was greater for neonates with multiple 
malformations than for single malformations. Four to seven fold associations were 
observed with skeletal, neural tube and heart abnormalities, and CL/P. The 
association of established diabetes with congenital malformations was nearly twice as 
strong among female neonates than among male neonates and no such variation was 
observed for associations with GDM 218. In addition, based on a cohort study of 2,060 
infants to mothers with GDM, congenital malformations, including CL/P, have been 
correlated to pre-pregnancy BMI and to the severity of diabetes 142. 
The risk of birth defects was investigated by Correa et al. (2012) in relation to 
DM and the lack of use of periconceptional vitamins or supplements containing folic 
acid using a population-based case-control study. Among 14,721 cases and 5,473 
controls, the risk of OFCs associated with DM in the absence of periconceptional use 
of MVIs containing folic acid increased significantly (ratio of 11:2 (cases: controls) 
and aOR of 13.84 [95% CI 3.01-63.68]) compared to mothers with DM and reported 
periconceptional MVI use (ratio of 23:27 and aOR of 2.17 [95% CI 1.20-3.93]). This 
result suggests that the periconceptional use of MVI may reduce the risk for birth 
defects among offspring of mothers with diabetes 127, 128. 
Abdominal obesity, aberrant glycemic control, hypertension, and 
hyperlipidemia are variably defined as a co-occurrence of metabolic syndrome 219. 
Some of the common co-morbidities of this diagnosis include increased oxidative 
stress and inflammation and compromised immune function 220. Investigation of this 
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syndrome, with the presence of obesity, DM, and hypertension may provide useful 
clues regarding birth defects associations 98.  
Previous studies have suggested an increased risk for having newborns with 
OFCs in diabetic mothers compared to non-diabetic mothers 207, 211, 221, 222. Although 
GDM has been also reported by previous studies to increase the risk for congenital 
birth defects 223-225, studies of the association between GDM and OFC are limited. 
Investigating the effect of maternal DM and GDM on the risk of OFC specific types 
may provide useful clues regarding the risk factors associated with the etiology of 
OFCs. 
Hypertension 
 Hypertension is a chronic medical condition in which the systemic arterial 
blood pressure is elevated to a level that may induce adverse effects such as 
cardiovascular damage. Normal blood pressure is 120/80 mm/Hg. High blood 
pressure is anything more than 140/90 mm/Hg. Dietary and lifestyle changes can 
improve blood pressure control and decrease the risk of associated health 
complications 226. Although no direct cause has been identified, there are many 
factors such as sedentary lifestyle, smoking, stress, hypokalemia 227, salt (sodium) 
sensitivity 228, alcohol intake 229 and vitamin D deficiency that increase the risk of 
developing hypertension 230. Hypertension is also caused by other conditions such as 
obesity 231. Lifestyle modification including dietary changes, physical exercise, and 
weight loss has been proven to significantly reduce blood pressure in people with 
hypertension 232.  
Epidemiology of Hypertension 
 Hypertension affects millions of persons in the United States, and less 
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than half of those with hypertension have their condition controlled. Using the 
National Health and Nutrition Examination Survey (NHANES) data, several studies 
have been conducted to estimate the prevalence of hypertension in the United States. 
A study has used the NHANES Survey 1999–2004 database, and found the overall 
prevalence of hypertension to be 29.3%. When compared with the 1999–2000 data 
set, there were non-significant increases in the overall prevalence of hypertension 233.  
A more recent study reported the prevalence of hypertension in the United States. 
During 2005-2008, approximately 68 million (31%) U.S. adults aged ≥18 years 
were having hypertension, and this prevalence has shown no improvement in 
the past decade and of these adults, 86% had their condition uncontrolled 234.  
 In 2012, a study was conducted to examine the prevalence and outcomes of 
primary and secondary chronic hypertension using a population-based sample of 
deliveries. During 1995-2008, the prevalence of primary and secondary hypertension 
increased significantly from 0.90% in 1995-1996 to 1.52% in 2007-2008 and from 
0.07% to 0.24%, respectively. Primary and secondary chronic hypertension were 
considerable for many maternal adverse outcomes, including acute renal failure, 
pulmonary edema, and preeclampsia, and accounted for a significant fraction of 
pregnancy complications 235. 
Maternal Hypertension and Cleft Lip and Cleft Palate Birth Defects 
Pregnancy in women with hypertension has various neonatal complications 
236. However, the effect of maternal hypertension of the risk of congenital 
malformations, including OFCs, has been understudied 237. In a study conducted to 
explore possible maternal factors associated with OFCs in the US population, the 
prevalence of pregnancy-associated hypertension was significantly higher in OFC 
                                                                                                                                                                                                                                                                                                                                                                                   
41 
group compared to controls. After adjustment for maternal age and tobacco smoking, 
multivariate models found Non-Hispanic Blacks with pregnancy-associated 
hypertension to be at lower risk for having a child with an OFC (aOR=0.09 [95% CI 
0.02-0.42]) as well as Hispanics (OR=0.79 [95% CI 0.63-0.98]). Researchers in this 
study suggested a role of the epigenetic DNA modification resulted from the non-
inherited (modifiable) factor, the pregnancy-associated hypertension, in determining 
whether the genes that direct the proper formation of the lip and palate are properly 
expressed 56.  
 A case-control study conducted in Thailand sought to identify the risk factors 
for congenital malformations between May 1987 to April 1988. CLPs were among 
the most common types of malformations. Risk factors significantly associated with 
malformations included maternal hypertension during pregnancy, maternal age > 35 
years, low maternal education levels, separated or divorced marital status, family 
history of similar abnormalities, an accident during pregnancy, and maternal illness 
during pregnancy 238. 
Although hypertension has been associated in a few studies with congenital 
malformations, maternal hypertension and the risk of having offspring with OFCs 
have been relatively understudied. Further investigation of this association may help 
in reducing the risk of OFCs. 
Metabolic Syndrome 
Metabolic syndrome is a combination of medical disorders that, when co-
occurring together, increase the risk of developing cardiovascular disease and 
diabetes 239, 240. In 2001, the Third Report of the U.S. National Cholesterol Education 
Program Expert Panel on Detection, Evaluation, and Treatment of High Blood 
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Cholesterol in Adults (NCEP/ATP III) provided a working definition of the metabolic 
syndrome based on five commonly measured clinical criteria and it requires at least 
three of the risk factors to be present: 1) central obesity: waist circumference ≥ 
102 cm or 40 inches (male), ≥ 88 cm or 36 inches (female); 2) dyslipidemia: TG ≥ 
1.7 mmol/L (150 mg/dl); 3) dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL 
(female); 4) blood pressure ≥ 130/85 mmHg; 5) fasting plasma glucose ≥ 6.1 mmol/L 
(110 mg/dl) 241. In 2004, the American Heart Association intended to update the 
NCEP ATP III definition as follows: 1) Elevated waist circumference: > 40 inches or 
102 cm (male), > 35 inches or 88 cm (female); 2) Elevated triglycerides: ≥ 150 mg/dL 
(1.7 mmol/L); 3) Reduced HDL (“good”) cholesterol: < 40 mg/dL (1.03 mmol/L) 
(male), < 50 mg/dL (1.29 mmol/L) (female); 4) Elevated blood pressure: ≥ 
130/85 mm Hg or use of medication for hypertension; 5) Elevated fasting glucose: 
≥100 mg/dL (5.6 mmol/L) or use of medication for hyperglycemia 242. The most 
recent definitions, though, are from the International Diabetes Federation (IDF) and 
from the American Heart Association/National Heart, Lung and Blood Institute 
AHA/NHLBI 243-245. The differences between these definitions are essentially the 
threshold for the parameters to define a syndrome abnormality, the number of 
abnormalities before the syndrome is deemed to be present, and whether there is a 
compulsory abnormality that is required to be present 246. 
Since 1947, several studies suggested that early onset of obesity, hyperplasia 
of normal adipocytes, and normal quantities of visceral abdominal fat may be 
associated with a favorable metabolic response in obese subjects 247, 248.  Keyes 
suggested that obesity for some was not a risk factor and might even be healthy 249. 
Bonora et al. concluded that a subgroup of obese individuals with a normal metabolic 
response is evident 250. Brochu et al. have also suggested that obese metabolically 
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normal subgroups must be taken into consideration in both clinical and research work. 
In fact, attempts at weight loss may be counterproductive 251. Kip et al. conducted a 
study to assess whether the contribution of obesity to cardiovascular risk is 
independent of the presence of metabolic syndrome. Data revealed that metabolic 
syndrome, but not BMI, predicts future cardiovascular risk in women. Results also 
indicated that normal-weight women with the metabolic syndrome have a 
significantly higher cardiovascular risk. However, overweight and obese women with 
normal metabolism have a relatively low cardiovascular risk. A possible explanation 
suggested by Kip et al. was that the measurement of BMI to define overweight and 
obesity does not quantify the magnitude or ratio of subcutaneous to visceral fat or 
muscle in an individual. The visceral fat area appears to be an important link between 
many components of the metabolic syndrome, such as dyslipidemia and hypertension. 
For a better precise clinical measurement, it is important to assess whether the 
participants with normal BMI and the metabolic syndrome have relatively high levels 
of visceral fat or, conversely, whether obese individuals with normal metabolic status 
have relatively low levels of visceral fat 252. 
Epidemiology of Metabolic Syndrome 
Many reports were undertaken to explore the prevalence of the metabolic 
syndrome around the world. However, the prevalence rates of the metabolic 
syndrome reported in the different studies have varied widely, mainly because of 
differences in the criteria used for defining the syndrome and the differences in the 
characteristics of the populations studied 253. 
Metabolic Syndrome in United States and Canada 
Between NHANES 1988 to 1994, more than 25% of the population in the 
United States had metabolic syndrome by NCEP criteria. A similar prevalence was 
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described for Canada. By the age of 60, the percentage affected in the United States 
increased to 40% 219.  
In 2003 to 2006, 34% of adults met the criteria for metabolic syndrome. Males 
and females between 40-59 years of age were about three times as likely as those 20-
39 years of age to meet the criteria for metabolic syndrome. By the age of 60, males 
were four times as likely as the youngest group to meet the criteria, while females 
were more than six times as likely. Non-Hispanic black males were about 50% as 
likely as non-Hispanic white males to meet the criteria for metabolic syndrome, while 
non-Hispanic black and Mexican-American females were about 150% as likely as 
non-Hispanic white females to meet the criteria. Overweight males were six times as 
likely while obese males were 32 times as likely as normal weight males to meet the 
criteria. Overweight females were about five times as likely as normal weight females 
to meet the criteria and obese females were more than 17 times as likely 254.  
Metabolic Syndrome in Europe 
Several studies on the occurrence of the metabolic syndrome in Europe have 
been reported and the criteria used to define the metabolic syndrome varied across the 
studies 255-265. However, it can be estimated that approximately 25% of the adult 
European population had the metabolic syndrome. Prevalence varied across the age 
group studied and geographic location. When NCEP and IDF criteria were compared, 
the IDF criteria usually gave a higher prevalence 253. 
Metabolic Syndrome in Latin America 
According to a meta-analysis 253, the prevalence of the metabolic syndrome, as 
defined by NCEP or WHO, is relatively high. Approximately 25% of the adult 
population had the metabolic syndrome, with the highest prevalence contributing to 
the Brazilian population (53%) 266. 
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Metabolic Syndrome in Asia 
The prevalence of metabolic syndrome was reported by several studies in 
Central Asia, Southeast Asia, China, and Japan. In India, A cross-sectional population 
based study reported the prevalence of metabolic syndrome in a local population in 
India. Out of 1,568 patients were referred to High Tech Hospital, 33.17% of males 
and 27.04% of females were diagnosed to have metabolic syndrome 267. Furthermore, 
a population-based survey of cohort of subjects in the Metropolitan city of Mumbai 
reported that 19.52% out of 548 subjects to have Metabolic syndrome. The overall 
prevalence of BMI (>23 kg/m2) was 79.01% 268. In Southeast Asia, less than one-fifth 
of the studied population in Southeast Asia had the metabolic syndrome 269, 270. In 
China, the general population had a relatively low prevalence, possibly because of the 
high waist circumference cut-off value of NCEP that was used for abdominal obesity 
criterion. In older Chinese subjects with type-2 diabetes, the prevalence was much 
higher 271-273. Finally, in Japan, the reported prevalence varied substantially from one 
study to another. Surprisingly, two reports in men indicated a prevalence up to 25% of 
the population 274, 275  
Metabolic Syndrome in the Middle East 
In the Eastern Mediterranean region, a study of adult female Saudi subjects 
found the prevalence of metabolic syndrome to be 16.1% and 13.6% according to IDF 
and ATP III definitions, respectively 276. The prevalence of metabolic syndrome in the 
Arab Gulf countries was 10%–15% higher than in most developing countries, with a 
higher prevalence among women. The proportion of metabolic syndrome in the Arab 
Gulf countries ranged from 20.7% to 37.2% using ATP III definition, and from 29.6% 
to 36.2% using the IDF definition 277. 
  In conclusion, the overall prevalence of the metabolic syndrome 
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demonstrates that metabolic syndrome is prevalent worldwide and that it increases 
with age and with BMI. The prevalence varied by race and ethnicity but the pattern 
was different for males and females. 
Metabolic Syndrome: The Underlying Causal Mechanism Linking Maternal Obesity, 
Diabetes, and Hypertension to OFCs? 
 There is a common link between hypertension, diabetes, and obesity 
illustrated by the causal relationship between the level of circulating insulin and 
diastolic pressure caused by obesity 278. Abdominal obesity, glucose intolerance, 
hypertension, and dyslipidemia are risk factors that comprise metabolic syndrome 279. 
The increasing global prevalences of NIDDM and hypertension are a result of rising 
rates of obesity 280, as well as hypertension 231 and have all been implicated in the 
development of congenital defects 141, 238. Obese women are at higher risk for 
developing NIDDM and, through pregnancy, at higher risk of developing GDM. 
Women who develop GDM later in pregnancy may also have had undetected 
metabolic problems earlier in the pregnancy 208. Since 1970, Navarrete et al. indicated 
a definitive relation between a maternal glucose metabolic disorder and congenital 
malformations and suggested research into the early phases of diabetic states in 
mothers pregnant of a deformed infant 281. However, obese women, even in the 
absence of diabetes, have been found to have impaired glucose metabolism 208. Forest 
et al. have revealed that among white women in their mid-30s, the prevalence of the 
metabolic syndrome is 3- to 5-fold increase in those with a history of pregnancy-
induced hypertension in their first pregnancy 282.  
McCarthy 130 has suggested that NIDDM results when pancreatic beta cells 
are unable to secrete sufficient insulin to maintain normoglycemia, typically in the 
context of increasing peripheral insulin resistance. The beta-cell abnormalities 
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fundamental to type-2 diabetes are thought to include both reduced beta-cell mass and 
disruptions of beta-cell function. Insulin resistance can be the consequence of obesity 
or of obesity-independent abnormalities in the responses of muscle, fat, or liver to 
insulin. Examples of susceptibility factors, given current evidence, that are likely to 
influence predisposition to OFCs by means of each of these mechanisms are shown 
(Figure 2-1).  
Abdominal obesity, aberrant glycemic control, and hypertension are variably 
defined as a co-occurrence of metabolic syndrome 219 and are substantially 
interrelated, reflecting substantial overlap in their etiology and mechanisms 283. 
Studies of the association between maternal bodyweight categories, DM and GDM, 
and hypertension and the risk of specific OFC types may substantially reduce the risk 
of OFCs associated with these conditions. 
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Figure 2-1. Pathways to Type-2 Diabetes Implicated by Identified Common 
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CHAPTER 3 
MATERNAL OBESITY AND UNDERWEIGHT AND THE RISK OF 
OROFACIAL CLEFTS1 
Abstract 
Objective To evaluate whether maternal underweight and obesity are independently 
associated with risk of orofacial clefts.  
Design Pooled analyses of population-based case–control studies. 
Setting A unique and large international consortium of case-control studies from 
Utah, Iowa, Norway (two studies 1996-2001 and (2000-2009)), and the U.S. National 
Birth Defects Prevention Study. 
Participants Mothers of 2,162 infants with cleft palate and cleft lip (CLP); 1,161 
infants with cleft lip only (CLO); 1,774 infants with cleft palate only (CPO); and 
10,633 controls.  
Main outcome measures Association of orofacial clefts with maternal pre-pregnancy 
weight classified by the body-mass index (BMI, kg/m2) for underweight, normal 
weight, overweight, and obesity. 
Results Maternal obesity (pre-pregnancy BMI >30), compared to normal weight 
(18.5<BMI>25), was associated with an increased risk of cleft palate with or without 
cleft lip (CP/L) (aOR=1.13 [95%CI 1.01-1.25]), after adjusting for maternal age, 
multivitamin use, smoking during pregnancy, alcohol use, and education level. We 
also found a marginal association between maternal underweight and CP/L (1.0 
[reference]; aOR=1.14 [95%CI 0.97-1.34]. CLO was not associated with underweight 
or obesity. Among college-graduates, there was no increased risk of cleft palate for 
                                                        
1 Coauthored by Hebah A. Kutbi and Ronald G. Munger.  
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either underweight (aOR= 0.84 [95% CI  0.58-1.21]) or obesity (aOR =1.01 [95% CI 
0.79-1.28]), but mothers with less than a completed college education had an 
increased risk of cleft palate for underweight (aOR =1.26[95% CI [1.05-1.51]) and 
obesity (aOR=1.17 [95% CI 1.05-1.32]).  
Conclusions Maternal obesity and underweight are both similarly associated with 
increased risk of orofacial clefts. These deviations from normal weight likely 
represent diverse metabolic, dietary, socioeconomic, and lifestyle factors that may be 
related to the causes of orofacial clefts. Interestingly, we found significant 
modification of the associations between maternal underweight and obesity and cleft 
risk by maternal education levels. Further analyses are needed to identify the 
pathways leading to the increased risk for orofacial clefts and more detailed 
assessment of socioeconomic status is needed. Our findings suggest that BMI may be 
an imprecise indicator of risk and there is a need to assess mothers for hyperglycemia 
and other underlying metabolic abnormalities early in pregnancy to reduce the risk of 
orofacial cleft in their offspring. 
Introduction 
Clefts of the lip and palate are among the most common structural birth 
defects and a public health problem 1, 2. In 2010 in the United States, an estimated 
4,437 live births per year had cleft lip or cleft palate 3. Several studies suggest that 
obesity, diabetes, or the underlying metabolic abnormalities known as the metabolic 
syndrome, may be involved in the pathogenesis of cleft lip and cleft palate 4-6. 
However, further studies are needed for a more complete understanding of the 
etiology of this disorder 7. 
 Maternal obesity in early pregnancy has been associated with an increased risk 
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of orofacial clefts (OFCs) in some studies. Yet, the magnitude of effect has varied 
across studies and the question remains unresolved 8-12. This question is especially 
relevant as obesity is leading global public health problem. Thus, even a modest 
effect of maternal obesity may be linked to a significant burden of OFCs. The role of 
maternal underweight is relatively understudied although it has potential adverse 
perinatal outcomes 13.  While underweight is a lesser problem in industrialized 
countries, a better understanding of the role of underweight may help in 
understanding the causes of OFCs in both industrialized and developing countries. 
 Obesity is usually defined as having a body-mass-index (BMI; weight in 
kg/height in M2) of  >30.0 kg/m2 14. Among adults, age-adjusted prevalence of obesity 
in 2007-2008 was 33.8%, with an overall 32.2% among men and 35.5% among 
women 14. It is expected that by 2015, 41% of adults in the United States will be 
obese 15. An increased bodyweight is associated with increased incidence of a number 
of conditions, including diabetes mellitus and cardiovascular disease. An increased 
risk for diabetes mellitus begins to rise at a BMI of greater than 30 kg/m2 16. Other 
risk factor that may contribute to a higher obesity risk is low educational attainment 
of mothers 17. We assessed the relationship between maternal BMI and the risk of 
clefts in a consortium of studies from Utah, Iowa, Norway, and the U.S. National 
Birth Defects Prevention Study. 
Methods 
Study Design & Data Collection 
 This study is a combined, unique, and large international consortium of 
population-based case-control studies from two separate studies from Iowa, Utah, the 
U.S. National Birth Defects and Prevention Study (NBDPS), and two Norwegian 
studies. The combined sample includes 15,726 women including 5,093 mothers of 
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children with OFCs and 10,633 mothers of unaffected children. Table 3-1 summarizes 
the types of clefts, the numbers, and the sources of samples. Data were available on 
self-reported pre-pregnancy maternal weight and height and other perinatal and 
demographic factors, which are used as covariates to control for potential 
confounding. Body-mass index (BMI) was computed as weight (kg)/height (m2) and 
used to define body weight categories as underweight (BMI<18.5 kg/ m2), normal 
weight (18.5-<25 kg/ m2), overweight (25-<30 kg/ m2) and obese (≥30 kg/ m2). 
Studies included in this current study are as follows:  
(1) Utah Study: A state-wide case-control study of clefts was conducted in 
Utah during 1995 to 2004 in collaboration with the Utah Birth Defects Network 
(UBDN) involving 561 cases with CL/P and 660 randomly selected unaffected births 
(from birth certificates) matched cases by month, year of birth, and gender of the 
child.  The UBDN staff members attempted to contact potential case and control 
mothers by mail to obtain consent for release of their names to USU investigators. 
Address updates were sought using available Internet services. If no mailing address 
was available, attempts were made to locate the mothers in person by field tracing 
that included visits to the last known home address and inquiries with neighbors. The 
UBDN later joined the National Birth Defects Prevention Study (NBDPS) described 
below. A detailed description of data collection is provided elsewhere 18.  
(2) Norway Facial Cleft Study: The Norway Facial Clefts Study (NCL) is a 
population survey of infants born with CL/P in Norway in 1996 through 2001. Data 
included 570 cases and their parents and a randomly selected control sample of 736 
infants born without birth defects in the same period 19. Extensive data on maternal 
behaviors, household factors and socioeconomics were available. The data collection 
is described elsewhere 20.  
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(3) Norway National Mother and Child Cohort Study: The Norwegian Mother 
and Child Cohort Study (MoBa), conducted by the Norwegian Institute of Public 
Health (NIPH, Oslo, Norway), is a cohort consisting of pregnancies recruited 
beginning in 1999 to 2008 21. Identified were 164 cases of C/P and 551 control 
mothers of which were randomly selected with matching to the case sample by year 
and state of birth.  Data on maternal health behaviors, demographic and 
socioeconomic characteristics, health problems and food behaviors were obtained 
during pregnancy between weeks 15 and 30 (data on risk and health behaviors is 
collected between 15 and 18 weeks). The study also involved follow-up interviews 
with the mother and child until the child is three years old.  
(4) Iowa Case-Control Sample: The Iowa Registry of Congenital and Inherited 
Disorders (IRCID) case-control sample consisted of about 287 cases with CL/P and 
302 controls born between 1987 through 1996. The control sample was randomly 
selected from all unaffected live births and matched to the affected sample by birth 
month, year and gender. Data on risk behaviors, socioeconomic characteristics and 
other relevant data, were obtained through telephone-based interviews and self-
administered forms were sent by mail 22.  
(5) National Birth Defects Population Studies: NBDPS samples with CL/P and 
control samples included multiple participating States. These include Arkansas, 
California, Georgia, Massachusetts, New Jersey, New York, North Carolina, Iowa, 
Texas, and Utah. NBDPS sample provided 3,491 CL/P cases and 8,357 control 
mothers, matched by State and birth year to the CL/P sample 23. 
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 SPSS statistical analysis version 20.0 was used to describe the characteristics 
of study population. Descriptive analysis was conducted in SPSS to examine the 
association between obesity and other factors, such as maternal age, smoking during 
pregnancy, multivitamin use, education (college graduate, high school graduate only, 
and less than high school graduate) and socioeconomic status. 
 Analysis of variance was used to examine the association between body mass 
index (BMI) and each selected covariates, such as maternal age, study site, smoking 
during pregnancy, multivitamin use, education, and socioeconomic status. 
 Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to 
estimate the relative risk for CL/P across the weight categories defined by BMI levels. 
Multiple logistic regression analysis was used to adjust for differences in maternal 
age, educational level of mother (college graduate, high school graduate only, and 
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less than high school graduate), multivitamin use during the first trimester of 
pregnancy, and history of smoking and alcohol use during the first trimester of 
pregnancy (yes versus no for each) and model the effect of body weight on OFC risk. 
Results 
 Among the case and control children, 58.6% (n=2,933) and 51.9% (n=5,480) 
respectively were boys. Among the case children, cleft lip only (CLO) accounted for 
22.8% (n=1,161), cleft palate only (CPO) 34.8% (n=1,774), and cleft lip with cleft 
palate (CLP) accounted for 42.5% (n=2,162) of cases. Within CLO cases, 1,053 and 
108 children cases were reported to have isolated and multiple birth defects, 
respectively. 1,809 cases had isolated CLP and 353 cases had multiple CLP. Within 
CPO cases, 1,313 and 461 CPO cases had isolated and multiple birth defects, 
respectively.  
Demographic characteristics of the sample appear in table 3-2. The mean ages 
of mothers of cases and controls and the maternal BMI were not significantly 
different at any site. Smoking during the index pregnancy period was common and 
associated significantly with the risk of OFCs among Utah subjects (p-value=0.002), 
Norway (p-value <0.001), and NBDPS studies (p-value <0.001). Use of alcohol by 
the mother during the index pregnancy was significantly more frequent (p-
value=0.011) among the case versus control mothers in Norway study; no significant 
associations were seen in the other studies. Maternal caffeine use during the first 
trimester was associated significantly with the risk of OFCs in MoBa study only (p-
value=0.023). Maternal employment was significantly associated with the risk of 
OFC in the Norway sample (p-value=0.019) and NBDPS sample (p-value=0.018), but 
was not among any other study sites. Maternal folic acid intake was significantly 
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associated with the risk of OFCs within Iowa (p-value=0.055) and NBDPS (p-
value=0.024) samples only. Maternal education was associated with the risk of OFC 
within NBDPS sample (p-value <0.001). 
The distribution of body weight categories varied considerably across study 
sites. However, in subgroup analyses maternal body weight categories were only 
significantly associated with the risk of OFCs within NBDPS sample group, where 
higher percent of cases among underweight and obese mothers were observed (6.6% 
and 20.6%) compared to controls (5.5% and 18.1%), respectively.  
Logistic regression models were used to evaluate the association between 
maternal BMI, maternal weight categories, and isolated and multiple OFCs combined 
(CLO, CLP, CPO, and all clefts). In a multiple logistic regression analysis that 
controlled for maternal age groups, maternal smoking during pregnancy, alcohol 
drinking, multivitamin use, and education (college graduate, high school graduate, 
and less than high school) shown in table 3-3, the estimated relative risk (adjusted OR 
(aOR) and 95% confidence intervals (CIs)) for having cleft lip and cleft palate (CLP) 
(aOR=1.15 [95%CI 1.00-1.32]), cleft palate with or without cleft lip (CP/L) 
(aOR=1.13 [95%CI 1.01-1.25]), and all clefts combined (aOR=1.12 [95%CI 1.01-
1.23]) increased significantly with maternal obesity. No effect of maternal obesity on 
CLO was observed (aOR=1.06 [95%CI 0.89-1.27]). Associations between maternal 
bodyweight categories and the risk of isolated clefts, including CLO, CLP, CPO, 
CP/L, and all isolated cleft types combined were similar but were on the margins of 
statistical significance. 
Table 3-4 illustrates the risk of isolated OFCs by maternal BMI categories by 
cleft types. Maternal body weight appeared not to be associated with any of the 
isolated cleft types. 
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Study Site   
Utah Norway CC1 Norway-MoBa2 Iowa CC3 NBDPS4 Total 
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
Maternal age in years + 
standard deviation (SD) 
27.0 +5.7 26.8+5.2 28.9+5.0 29.23+4.8 29.9+5.0 30.0+4.6 26.7+5.3 27.1+4.9 26.9+6.2 26.9+6.1 27.2+6.0 27.2+5.9 
Paternal age in years + SD 29.4+6.4 28.9+5.6 28.9+5.0 31.8+5.5 32.9+6.0 32.9+5.6 26.7+5.3 27.1+4.9 30.0+6.9 29.8+6.8 29.9+7.0 29.9+6.8 
Body-mass index (BMI; 
kg/M2) + SD 
24.3+5.0 24.2+5.3 23.7+4.4 23.4+3.7 23.9+4.2 24.1+4.2 23.5+5.2 23.0+4.4 25.3+6.2 25.0+5.8 24.9+5.8 24.8+5.5 
Maternal BMI categories             
Underweight5 % 6.6 6.8 3.3 3.7 5.0 4.4 6.3 8.0 6.7 5.5 6.3 5.4 
Normal Weight6 % 55.3 59.5 3.3 3.7 63.6 62.6 65.4 65.4 49.1 51.4 53.4 54.3 
Overweight7 % 25.3 21.5 19.5 18.8 19.0 23.1 19.7 17.6 23.6 25.1 23.0 24.0 
Obesity8 % 12.8 12.1 8.1 7.0 12.4 9.9 8.7 9.0 20.7 18.1 17.3 16.2 
Smoker % 13.5 8 41.6 31.8 27.6 23.8 25.1 22.2 21.2 16.2 23.1 17.4 
Alcohol use in 1st trimester 
% 
7.5 6.4 38.1 30.5 12.7 14 34.5 34.8 22.9 22.5 23.3 22.0 
Maternal employment % 88.1 85.6 80.2 85.1 78.6 79.2 N/A N/A 69.5 71.7 73.3 74.0 
Maternal caffeine use in 1st 
trimester % 
98.6 98.3 89.6 89.8 86.2 92.4 85.0 83.8 70.9 69.8 78.4 75.3 
Multivitamin use % 75.8 75.6 37.2 40.6 70.7 74.6 63.6 71.1 82.2 83.9 75.0 79.5 
Education <  High School % 8.0 6.5 16.1 11.4 5.7 2.6 9.8 7.6 19.9 17.3 17.1 15.2 
Education >  College % 26.7 30.5 39.6 40.9 62.7 62.4 18.1 22.5 26.0 31.6 28.3 33.4 
High School graduate % 65.2 63.0 44.2 47.7 31.6 34.9 72.1 69.9 54.2 51.1 54.6 51.4 
Male % 59.2 60.6 60.3 53.3 58.2 55.2 53.8 54.0 58.6 50.9 58.6 51.9 
 
1Norway case-control study.                                                                                                                                                                        
2Norway mother-baby study. 
3Iowa case-control study. 
4National Birth Defect Prevention study. 
5Underweight defined as BMI <18.5. 
6 Normal weight defined as =>18.5, <25 BMI. 
7Overweight defined as =>25, <30 BMI. 
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Table 3-3. Risk of Orofacial Clefts by Maternal Body Weight Categories and Cleft Types. 
 
Maternal  
Body Mass Index 
(BMI2) Group 
Adjusted odds ratios (aORs)3 and 95 percent confidence intervals (CIs) by Type of Clefts 
Cleft Lip Only Cleft Lip and Palate Cleft Palate Only Cleft Palate with or 
without Cleft Lip 
All Clefts 
Underweight  
BMI  <18.5 
1.05 [0.80-1.38] 1.11 [0.90-1.36] 1.18 [0.95-1.48] 1.14 [0.97-1.34] 1.13 [0.97-1.31] 
Normal weight  
BMI >18.5, < 25 
1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 
Overweight  
BMI  >25, <30 
1.01 [0.92-1.10] 0.99 [0.88-1.12] 1.04 [0.91-1.18] 1.01 [0.92-1.11] 1.01 [0.92-1.10] 
Obese  
BMI  >30 
1.06 [0.89-1.27] 1.15 [1.00-1.32] 1.10 [0.95-1.27]  1.13 [1.01-1.25] 1.12 [1.01-1.23] 
 
1Include isolated orofacial clefts and those with multiple birth defects. 
2Body mass index, weight in kg/height in M2. 
3Covariates in multiple logistic regression models include study site, maternal age, maternal smoking during pregnancy, alcohol drinking, 
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Table 3-4. Risk of Isolated Orofacial Clefts by Maternal Body Weight Categories by Cleft Types 
 
Maternal  
Body Mass Index 
(BMI1) Group 
Adjusted odds ratios (aORs)2 and 95 percent confidence intervals (CIs) by  Cleft Types 
Isolated Cleft Lip 
Only 
Isolated Cleft Lip 
and Palate 
Isolated Cleft Palate 
Only 
Isolated Cleft Palate 
with or without Cleft 
Lip 
All Isolated Clefts 
Underweight  
BMI  <18.5 
1.02 [0.76-1.37] 1.11 [0.89-1.39] 1.10 [0.85-1.43] 1.11 [0.93-1.34] 1.09 [0.93-1.29] 
Normal weight  
BMI >18.5, < 25 
1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 
Overweight  
BMI  >25, <30 
1.00 [0.85-1.18] 1.00 [0.87-1.13] 1.01 [0.87-1.17] 1.00 [0.90-1.11] 1.00 [0.91-1.10] 
Obese  
BMI  >30 
1.06 [0.88-1.28] 1.11 [0.96-1.29] 1.12 [0.94-1.32]  1.11 [0.99-1.25] 1.10 [0.99-1.23] 
 
1Body mass index, weight in kg/height in M2 
2Covariates in multiple logistic regression models include study site, maternal age, maternal smoking during pregnancy, alcohol drinking, 
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The association between OFC and maternal education level, shown in table 3-
5, revealed that the risk of OFCs was significantly higher in mothers who were not 
high school graduates compared to high school graduate mothers, with having college 
graduate group as a reference. The risk in high school graduate only for CLP, CPO, 
CP/L, and all cleft cases increased significantly (aORs of 1.36 [95% CI 1.20-1.54], 
1.26 [95% CI 1.11-1.44], 1.32 [95% CI 1.20-1.45], and 1.24 [95%CI 1.14-1.35], 
respectively). 
Adjusted odds ratios by cleft type related to maternal body weight was 
stratified by two levels of maternal education (less than college graduate versus 
college graduate) (table 6). Because overweight seemed similar to normal weight in 
that no effect on increased risk was observed, maternal overweight and normal weight 
were combined in the reference group. This is also important because the data become 
sparse when split into many subgroups. After controlling for maternal age, maternal 
smoking during pregnancy, alcohol drinking, and multivitamin use, the risk of OFC 
was higher for all body weight categories, including maternal underweight (aOR=1.23 
[95% CI 1.02-1.49]), obesity among those with lower education levels (aOR=1.16 
[1.03-1.31]). No significant associations were found with BMI among mothers who 
were college graduates (table 3-6).  
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Table 3-5. Risk of Orofacial Clefts1 by Maternal Education Level by Cleft Type 
 
Education Level 
Adjusted odds ratios (aOR)2 and 95 percent confidence intervals (CI) by Cleft Types  
Cleft Lip Only Cleft Lip and Palate Cleft Palate Only Cleft Palate with or 
without Cleft Lip 
All Clefts 
College graduate 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 1.0 [Reference] 
High School graduate only 1.02 [0.87-1.19] 1.36 [1.20-1.54] 1.26 [1.11-1.44] 1.32 [1.20-1.45] 1.24 [1.14-1.35] 
< High School graduate 0.94 [0.72-1.22] 1.85 [1.52-2.25] 1.28 [1.02-1.59] 1.46 [1.23-1.73] 1.40 [1.21-1.62] 
 
1Isolated orofacial clefts and those with multiple birth defects 
2Covariates in multiple logistic regression models include study site, maternal age, maternal smoking during pregnancy, alcohol use, multivitamin use, and 
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Adjusted odds ratios by cleft type were determined within each study site after 
controlling maternal age, maternal smoking during pregnancy, alcohol drinking, and 
multivitamin use, using CIs of 95% (table 3-7). In the Utah study, maternal 
underweight appeared to be protective against the risk of having a child with CLO 
(1.0 [reference]; aOR=0.16 [0.04-0.70]), while it appeared to increase the risk for all 
CL (aOR=1.66 [95% CI 1.01-2.72]). 
The total sample indicated a significant high risk for all cleft lip and all cleft 
palate associated with maternal obesity (1.0 [reference]; aOR=1.13 [95% CI 1.00-
1.26]) and 1.13 [1.01-1.25]). Other maternal categories did not show any effect on the 
risk of cleft. 
 
 Table 3-6. Adjusted1 Odds Ratio (aORs) and 95%  Confidence Intervals (CI) of 
Cleft Palate, with or Without cleft lip, Isolated or With Multiple Birth Defects By 





Maternal level  
of education 














Normal Weight BMI >18.5, < 25; and 












Normal Weight BMI >18.5, < 25; and 






1Covariates in multiple logistic regression models include study site, maternal age, maternal 
smoking during pregnancy, alcohol use, and multivitamin use. 
2Body mass index, weight in kg/height in M.2 
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Table 3-7. Adjusted Odds Ratios (aORs)1 and 95 Percent Confidence Intervals (CIs) of Isolated and Multiple OFCs Combined by maternal 
Body Mass Index group by cleft type and study site 
 
Study site Maternal Body Weight 
Category 
Adjusted odds ratios by cleft type 
Cleft lip only All Cleft palate2 All Cleft Lip All Clefts 
 
Utah 
Underweight     
BMI <18.5 
0.16 [0.04-0.70] 1.13 [0.68-1.86] 0.56 [0.30-1.04] 0.85 [0.52-1.37] 
Normal weight   
BMI >18.5, < 25 
1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
Overweight       
BMI >25, <30 
1.03 [0.65-1.63] 1.12 [0.82-1.52] 1.15 [0.84-1.58] 1.09 [0.82-1.46] 
Obese      
BMI >30 
1.06 [0.61-1.85] 1.19 [0.81-1.76] 1.13 [0.76-1.69] 1.16 [0.81-1.66] 
 
Norway CC 
Underweight     
BMI <18.5 
0.66 [0.22-2.00] 1.28 [0.70-2.34] 0.95 [0.49-1.86] 1.11 [0.63-1.97] 
Normal weight   
BMI >18.5, < 25 
1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
Overweight       
BMI >25, <30 
1.10 [0.67-1.80] 1.16 [0.85-1.58] 0.99 [0.70-1.38] 1.13 [0.85-1.50] 
Obese                 
BMI >30 




Underweight     
BMI <18.5 
0.00 0.52 [0.17-1.59] 0.32 [0.07-1.45] 0.46 [0.15-1.41] 
Normal weight   
BMI >18.5, < 25 
1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
Overweight       
BMI  >25, <30 
0.729 [0.26-2.61] 0.73 [0.42-1.27] 0.88 [0.49-1.59] 0.74 [0.44-1.25] 
Obese                 
BMI >30 





Underweight     
BMI <18.5 
1.15 [0.40-3.28] 1.05 [0.53-2.05] 0.99 [0.46-2.11] 1.09 [0.59-2.03] 
Normal weight  
BMI  >18.5, < 25 
1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
Overweight        
BMI >25, <30 
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Study site Maternal Body Weight 
Category 
Adjusted odds ratios by cleft type 
Cleft lip only All Cleft palate2 All Cleft Lip All Clefts 
Obese                 
BMI >30 




Underweight     
BMI <18.5 
1.27 [0.94-1.74] 1.16 [0.96-1.41] 1.23 [1.01-1.51] 1.19 [0.99-1.41] 
Normal weight  
BMI  >18.5, < 25 
1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
Overweight        
BMI >25, <30 
0.98 [0.81-1.18] 0.99 [0.88-1.11] 0.96 [0.85-1.08] 0.99 [0.89-1.09] 
Obese                
BMI  >30 
1.05 [0.85-1.29] 1.15 [1.02-1.30] 1.12 [0.99-1.28] 1.13 [1.01-1.27] 
 
Total sample 
Underweight     
BMI <18.5 
1.05 [0.80-1.38] 1.14 [0.97-1.34] 1.10 [0.92-1.31] 1.13 [0.97-1.31] 
Normal weight   
BMI >18.5, < 25 
1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
Overweight       
BMI  >25, <30 
1.01 [0.92-1.10] 1.01 [0.92-1.11] 0.99 [0.90-1.10] 1.01 [0.92-1.10] 
Obese                
BMI  >30 
1.06 [0.89-1.27] 1.13 [1.01-1.25] 1.13 [1.00-1.26] 1.12 [1.01-1.23] 
 
1Covariates in multiple logistic regression models include study site, maternal age, maternal smoking during pregnancy, alcohol use, maternal education (3-
levels), and multivitamin use. 
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Discussion 
Statement of Principal Findings 
This study provides evidence that maternal obesity increases the risk of having 
a child with a cleft palate with or without cleft lip (CP/L). Maternal underweight 
appears to increase the risk of CP/L in the offspring. The association between low 
level of maternal education level and increased risk of CLP, CPO, CP/L, and all clefts 
was significant, while among mothers with higher education, underweight and obese 
were not associated with an elevated risk for orofacial clefts (OFCs).  
Strengths of the Study  
The current study has several strengths. It represents the largest international 
consortium of case-control study to date with multiple countrywide sites in Europe 
and statewide sites in the US. The study is population-based and relatively robust 
against selection bias. OFC cases were drawn from birth defects registries. Controls 
were randomly selected from centralized birth records. Data obtained from the birth 
defect registries and birth records are rich data sources with respect to information on 
potential confounders. However, information on potential confounders were collected 
from participants’ interview. The study was designed to use well-defined procedures 
for case definition and careful classification of OFCs and associated conditions by 
clinical specialists.   
In some studies, conclusions about the association between maternal obesity 
and orofacial clefting were limited by small number of cases 5, 9, 12, 24. The present 
study was designed to test maternal weight hypotheses in relation to OFCs.  High 
quality data were available on several relevant covariates to control for potential 
confounding. Statistical analyses were conducted for both isolated and non-isolated 
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clefts combined and cleft type. The effects of maternal underweight, overweight, and 
obesity on the risk of orofacial cleft were all evaluated. As obesity is an epidemic 
health problem, a modest effect of maternal obesity can be linked to a significant 
burden of OFCs. Maternal underweight is associated with several adverse outcomes. 
Nevertheless, it remains an understudied problem. Results of this study confirmed that 
maternal obesity increases the risk of having a child with a CLP, CP/L, and all OFC 
types combined, while no effect of obesity on CLO was observed. Maternal 
underweight appeared to increase the risk of CP/L in the offspring. The association 
between low level of maternal education level and the risk of all OFC types was 
significant, while among mothers with higher education, underweight and obesity 
were not associated with risk of OFCs.  
Limitations of the Study 
Potential limitations of this study include the use of self-reported pre-
pregnancy weight and height and the possibility of recall bias among underweight and 
obese women 25. Data on exposures to smoking, multivitamin intake and 
socioeconomic status were limited to dichotomous exposure levels, thus residual 
confounding related to these factors is a possibility. As in all case-control studies, 
recall bias is a concern. Additionally, weight association with orofacial clefts was 
modified by the socioeconomic status as indicated by mother’s level of education, 
which is a limited measure of socioeconomic status.  
Strength and Weaknesses in Relation to Other Studies 
With the rising rates of excess weight among pregnant women 26, the current 
findings of an association between maternal obesity and OFCs in the offspring is a 
major public health concern. Studies of the association between pre-pregnancy 
maternal weight and risk of OFCs have produced inconsistent findings that may be 
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related to variations in population sample size, definitions of OFC subtypes, lack of 
consideration of maternal underweight, and inadequate control of potential 
confounding factors.   
In the present study, a positive association was found between both maternal 
underweight and obesity in early pregnancy and isolated and multiple OFC groups 
combined in the offspring. Similarly, Waller et al. reported that mothers who were 
underweight had no significant increase or decrease in the risk for birth defects, 
except for a significant increase in risk for cleft lip with or without cleft palate 
(aOR=1.35 [95% CI 1.04-1.76] 11. A meta–analysis conducted to assess current 
evidence of the association between maternal overweight, maternal obesity, and 
congenital anomaly also reported increased risks for CP (aOR=1.23 [95% CI 1.03-
1.47]) and CLP (aOR=1.20 [95% CI 1.03-1.40]) 6. Rankin et al. (2010) found an 
overall increased risk of congenital anomalies in women who were obese and 
underweight compared with women of recommended weight, but no association 
between maternal underweight and OFCs was found, OR=1.84 [95% CI 0.55–6.25]. 
This study included only 44 infants with OFCs 27.  
The association of obesity with clefts has been observed in a few other studies, 
although low numbers of cases limited their statistical power 5, 27, 28. Cedergren and 
Kallen (28) observed modest increases in the risk of CP and CL/P associated with 
pre-pregnancy BMI of  >29, while another case-control study reported an increase in 
the birth prevalence of all OFCs among women with BMI of ≥ 30 as compared with 
those with a BMI of < 30, OR=1.7 [95% CI 1.1-2.8] 9. Oddy et al. found twofold 
increased odds of having infants with OFCs in mothers with a BMI of ≥ 30, 
aOR=1.97 [95% CI 0.73-5.32], where only 6 mothers out of 48 were classified as 
obese 24. Recently, a population-based case-control study conducted in Florida found 
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obese women to experience increased odds of having a child with CL/P after 
controlling for maternal race, education, smoking, marital status, nativity, and 
maternal age (OR=1.25 [95% CI 1.05-1.48] and CP, OR=1.32 [1.07-1.62]). However, 
in this same study, the offspring of underweight mothers were not at a higher risk of 
OFCs 29. One limitation of their study is the lack of information on intake of vitamin 
supplement, which might have confounded the associations between pre-pregnancy 
maternal underweight/obesity and clefts. 
Similar to our findings, there was a strong association between CP/L and 
obesity but not with CLO 11. We also found a significant positive association when we 
combined CP with CL and all cleft palate. A previous study indicated a possible effect 
of maternal obesity on cleft palate malformation through the indirect influence of 
excess adiposity related to the bioaccumulation and release of dioxins, causing cleft 
palate in mice 30. Thus, our results suggest the associations with maternal bodyweight 
are specific to cleft palate and not to cleft lip. 
A case-control study reported an increased risk of isolated and multiple birth 
defects by maternal GDM in the presence of maternal obesity after adjusting for 
potential confounders 31. Marengo et al. reported a positive association between BMI 
and CPO among non-diabetic mothers (p< 0.05). For cleft lip, however, the 
prevalence was statistically elevated only among the non-diabetic mothers with class-
3 obesity (BMI ≥40), aOR=1.55 [95 % CI 1.14 -2.07]. Authors of this study found 
that smoking and education were not confounders of the association between BMI 
and birth defects. Therefore, they adjusted for maternal race/ethnicity and maternal 
age only 32 . In addition, the percentage of obese mothers reported in their sample was 
22.70%, but the prevalence of obesity within mothers of OFC cases was not 
described. Stott-Miller et al. reported a very modest elevation in risk of OFCs in 
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relation to maternal obesity. This could be due to residual confounding related to data 
collection, imprecision of primary exposure that may have biased the results, and/or 
the considerable amount of missing data for maternal BMI and pre-pregnancy weight 
8.   
Elevated risks for OFCs with increasing BMI were not observed in some other 
studies. Shaw et al. (2000) reported insignificant ORs for the risk isolated CL/P, 
aOR=1.0 [95% CI 0.6-1.6]; isolated CP, aOR=1.1 [0.6-2.0]; multiple CL/P, aOR=1.0 
[ 0.5-2.1]; and multiple CP, aOR=1.6 [0.8-3.4] 33. However, there were too few cases 
with maternal pre-pregnancy obesity studies to obtain valid adjusted estimates of the 
ORs. Villamor et al. (2008) evaluated the risk of OFCs in relation to pre-pregnancy 
weight change and interpregnancy interval. Data revealed an increased risk of isolated 
CP 2.3 times [95% CI 1.4-4.0] within women whose second-pregnancy BMI was ≥ 3 
units higher than their first-pregnancy BMI as compared with women whose BMI did 
not change significantly, while the BMI change was not related to the risk of cleft lip 
10. 
Implications for Clinicians and Policymakers 
What mechanisms could link maternal underweight and obesity to OFCs in the 
offspring? Whatever the underlying mechanism behind the observed associations is, 
maternal underweight and obesity appear to increase the risk for CP/L malformations 
but only in the less educated mothers. It is possible that the educated mothers have the 
characteristic of being “obese but metabolically healthy” or “underweight but 
metabolically healthy.” These terms describe a subset of people who seem to be 
protected against obesity- and underweight-related metabolic complications 34-39. As 
the association between maternal bodyweight and the risk of CP/L was significant, 
                                                                                                                                                                                                                                                                                                                                                                                   
90 
while no association with CLO existed, further investigation may yield insight into 
lip-palate-specific mechanisms of development.  
A possible explanation for the association between maternal obesity and OFCs 
is undetected type-2 diabetes with hyperglycemia and insulin resistance. A previous 
study reported that even in the absence of gestational diabetes, obese women were 
found to have an impaired glucose metabolism 40, which may be associated with an 
elevated risk for OFCs 5, 41, 42. Another possibility is that cases involved in the current 
study included “obese but metabolically healthy” or “underweight but metabolically 
unhealthy” individuals. These terms describe a subset of people who seem to be 
protected against obesity-related metabolic complications and individuals who are 
underweight but, like people with overt obesity, are insulin resistant and predisposed 
to type-2 diabetes and hypertriglyceridemia, respectively. Maternal body size, both 
underweight and obesity, appears to be an indirect measure of cleft risk.  Up to one-
third of obese persons are “metabolically healthy” 34-39 and this state of “metabolically 
healthy obesity” was correlated with higher educational status in the present study. 
Likewise, a substantial proportion of underweight persons might be “metabolically 
unhealthy.” 
Another possible explanation for the association between maternal obesity and 
OFCs could be improper nutrition. Shaw et al. (1995) and Itikala et al. (2001) 
suggested a possible role of folic acid deficiency on increasing the risk for OFCs 43, 44, 
while other studies reported inconsistent findings 45, 46. Additionally, high dietary 
glycemic load intake was found to be more common among mothers of OFC cases 47, 
48. Hendricks et al. (2001) have suggested a possible role of maternal poor glycemic 
control, independent of diabetes diagnosis, on the risk of OFCs 49. Previous findings 
provide evidence for higher levels of insulin resistance among obese patients 50-52. 
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Thus, the joint effect of abnormal glucose metabolism and obesity provide evidence 
of a synergistic effect on the risk of OFCs. Although the development of facial 
structure occurs within the first trimester of pregnancy, there are only a few data on 
glucose screening tests before 24 weeks of gestation. Further studies on appropriate 
methods for diabetes testing in early pregnancy are recommended. 
Our results also revealed significant associations between maternal education 
levels and the risk of CLP and all cleft palates, with a significant higher risk in CLP 
and all cleft cases, while Cedergren & Kallen 28 produced inconsistint finding of a 
weak association between maternal education levels, and maternal obesity and infant 
clefts. This may relate to the limited number of subjects with a known BMI in their 
study. However, authors suggested a possible indirect association through the effect 
of maternal obesity at low maternal education.  
Conclusions  
Maternal underweight and obesity are significantly associated with the risk of 
CPs but not CLO. The metabolic abnormalities underlying the increased risk are 
unknown and require further study. Surprisingly, a strong modification of the 
association was found by maternal education. It is possible that the BMI is just an 
indirect measure for the risk and college educated mothers who are obese are more fit 
and metabolically healthy than obese mothers with lower education levels. A more 
detailed assessment of socioeconomic status is needed. In addition, our findings 
highlight the need to assess the obese mothers for hyperglycemia early in pregnancy 
to reduce the risk of OFCs in their offspring. 
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 CHAPTER 4 
THE ROLE OF GESTATIONAL DIABETES MELLITUS AND  
HYPERTENSION ON THE RISK OF OROFACIAL CLEFTS IN UTAH 1 
Abstract 
Objective: To evaluate whether maternal gestational diabetes mellitus (GDM) and 
hypertension are independently associated with risk of orofacial clefts. 
Methods: A statewide case-control study of clefts in Utah during 1995 to 2004, in 
collaboration with the Utah Birth Defects Network (UBDN) involved mothers of 562 
infants with cleft, in which 430 cases were classified as isolated cleft cases and 133 as 
all multiples, syndromic, or chromosomal clefts, matched with 658 controls randomly 
selected unaffected births (from birth certificates) matched to cases by month, year of 
birth, and gender of the child. Descriptive analysis was conducted in SPSS to examine 
the association between GDM, hypertension, and orofacial clefts (OFCs). Odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated to estimate the relative risk 
for cleft lip with or without cleft palate (CL/P), cleft palate only (CPO), and all clefts 
(isolated and non-isolated clefts combined) according to the presence of diabetes or 
hypertension. Adjusted ORs (aORs) include control for potential confounding due to 
factors such as maternal smoking, periconceptional multivitamin use, maternal 
education level, body-mass-index (BMI), and maternal age. 
Results: Maternal GDM was significantly associated with isolated clefts (aOR=2.63 
[CI 95% 1.30-5.34]) and non-isolated clefts (aOR=2.66 [95% CI 1.015-6.97]). 
Maternal hypertension was significantly associated with non-isolated clefts 
(aOR=6.56 [95% CI 2.12-19.77]) and results were suggestive for isolated clefts 
                                                        
1 Coauthored by Hebah A. Kutbi and Ronald G. Munger. 
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(aOR=2.56 [95% CI 0.91-7.15]). We found a further increased risk of OFCs among 
GDM vs. non-GDM mothers who were obese (Body Mass Index (BMI>30) for 
isolated clefts (aOR=4.96 [1.26-19.51]) and for non-isolated clefts (aOR=14.21 [2.52-
80.21]). Mothers with hypertension who were also obese had an elevated risk for non-
isolated OFCs only (aOR=29.88 [95% CI 2.45-363.83]). 
Conclusions: Both GDM and hypertension were associated with OFCs, suggesting a 
possible existence of underlying abnormalities related to metabolic syndrome prior to 
pregnancy. Screening for diabetes and hypertension earlier in the periconceptional 
period may be needed to reduce the risk of OFCs in the offspring.   
Introduction 
Maternal diabetes mellitus (DM) 1-3 and hypertension 4, 5 have been implicated 
in several studies as possible etiological factors of various infant congenital 
malformations. Orofacial clefts (OFCs) are among the most frequent congenital birth 
defects in human 6. However, further studies are needed for a more complete 
understanding of the etiology of this disorder 7. 
Diabetes mellitus is a group of metabolic diseases results from defects in 
insulin secretion, insulin action, or both and characterized by chronic hyperglycemia 
with disturbances of carbohydrate, fat and protein metabolism. Three main types of 
diabetes have been defined: type-1, type-2, and gestational diabetes 8. Type-1 diabetes 
mellitus or insulin-dependent diabetes mellitus (IDDM) is partly inherited and then 
triggered by certain infections. It results from a T-cell mediated autoimmune 
destruction of the pancreatic beta cells in genetically predisposed individuals 9. Type-
2 diabetes or non-insulin-dependent diabetes mellitus (NIDDM) is due primarily to 
lifestyle factors and genetics 10. Type 1 and 2 are both conditions that can be treated 
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but not cured. Hence, diet, exercise, and use of appropriate medications to keep blood 
sugar levels as close to normal "euglycemia" can be achieved 11. Since 1970, 
Navarrete et al. indicated a definitive relation between a maternal glucose metabolic 
disorder and congenital malformations and suggested research into the early phases of 
diabetic state in mothers of malformed infants 12. 
Gestational diabetes mellitus (GDM) is a condition in which women without 
previously diagnosed diabetes exhibit high blood glucose levels (particularly during 
third trimester of pregnancy) when their bodies do not secrete excess insulin required 
during pregnancy 13.  However, women with GDM are at high risk for having or 
developing diabetes when they are not pregnant 14. It has been predicted that women 
who develop GDM later in pregnancy may also have had undetected metabolic 
problems earlier in the pregnancy 15.  
Hypertension is a chronic medical condition in which the systemic arterial 
blood pressure is elevated, increasing the blood pressure to a level that induces some 
adverse effects such as the cardiovascular damage. Normal blood pressure is 
120/80 mmHg, while high blood pressure is anything more than 140/90 mmHg 16. A 
case-control study conducted in Thailand sought to identify the risk factors for 
congenital malformations from May 1987 to April 1988. Cleft lip or cleft palate was 
among one of the most common types of malformations. Maternal age >35 years, low 
maternal education levels, separated/divorced marital status, family history of similar 
anomalies, an accident during pregnancy, maternal illness during pregnancy, and 
maternal hypertension during pregnancy were significantly associated with the risk of 
orofacial clefts (OFCs) 4. 
There is a substantial overlap between diabetes and hypertension, reflecting 
substantial overlap in their etiology and mechanisms. Among all diabetics, 
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hypertension is found in over 70% 17. Common pathways shared by DM and 
hypertension include Sympathetic Nervous System, Renin-Angiotensin-Aldosterone 
System, oxidative stress, adipokines, and insulin resistance (Fig. 4-1). These pathways 
may interact and influence each other.   
Abdominal obesity, aberrant glycemic control, hyperlipidemia, or 
hypertension is variably defined as co-occurrence of metabolic syndrome 18. Mothers 
who develop GDM later in pregnancy may have had undiagnosed type-2 DM and are 
susceptible to acquire DM later in life 15. Some of the common co-morbidities of 
GDM include increased oxidative stress and inflammation and immune dysfunction 
19. Investigation of metabolic syndrome, with the presence of diabetes, hypertension, 
and other more serious physiologic consequences, may provide useful clues regarding 
birth defects associations 20. We assessed the relationship between maternal 
gestational diabetes and hypertension and the risk of OFC. These two risk factors are 
hypothesized to cause cleft lip and cleft palate via metabolic abnormalities that affect 
fetal development. This set of related hypotheses was examined in analyses of data 
from the Utah cleft study.  
Materials and Methods 
A statewide case-control study of clefts was conducted in Utah during 1995 to 
2004 in collaboration with the Utah Birth Defects Network (UBDN). The UBDN staff 
members attempted to contact potential case and control mothers by mail to obtain 
consent for release of their names to USU investigators. Address updates were sought 
using available Internet services. If no mailing address was available, attempts were 
made to locate the mothers in person by field tracing that included visits to the last 
known home address and inquiries with neighbors. Interviews with mothers were
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Figure 4-1. Summary of Putative Pathophysiologic Mechanisms in the 
Development of Hypertension in Diabetes Mellitus. RAAS_Renin- Angiotensin-
Aldosterone System; SNS_Sympathetic Nervous System; VSMC_Vascular Smooth 





                                                                                                                                                                                                                                                                                                                                                                                   
101 
conducted primarily by telephone; however, personal interviews were completed if no 
telephone was available. The interview included questions on demographic 
characteristics of the biologic parents, a reproductive health and pregnancy history, 
supplement use, medications, medical conditions, and smoking and alcohol use. Each 
mother received an individualized, color-coded pregnancy calendar that was 
generated based on the date of delivery of her index child and the self-reported 
gestational length. This visual aid was intended to assist mothers in recalling activities 
and timing of events during various periods referred to. Color-coding of the calendars 
indicated the reference periods including the 3-month period before the estimated date 
of conception and three trimesters. Interview materials were translated into Spanish, 
and a bilingual interviewer contacted mothers speaking Spanish only. The UBDN 
later joined the National Birth Defects Prevention Study (NBDPS). A detailed 
description of data collection is provided elsewhere 22.  
Combined samples involved 375 cases with cleft lip with or without cleft 
palate (CL/P), 187 cases with cleft palate only (CPO), and 658 randomly selected 
unaffected births matched cases by month, year of birth, and gender of the child. Data 
were available on pre-pregnancy maternal weight and height and other perinatal and 
demographic factors, which were used as covariates to control for potential 
confounding. Body-mass-index (BMI) was computed as weight kilograms 
(kgs)/height (m2) and used to define body weight categories as underweight 
(BMI<18.5 kg/ m2), normal weight (18.5- <25 kg/ m2), overweight (25-<30 kg/ m2) 
and obese (≥30 kg/ m2). 
SPSS statistical analysis version 20.0 was used to describe the characteristics 
of study population. Descriptive analysis was conducted in SPSS to examine the 
association between maternal GDM and hypertension and other factors, such as 
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maternal age, history of smoking (three months prior to conception), multivitamin use 
during the first trimester of pregnancy, and education level (college graduate, high 
school graduate only, and less than high school graduate) and alcohol consumption. 
 Simple Chi-square analysis of contingency tables for categorical analysis was 
used to examine the association between each independent variable and selected 
covariates, such as maternal educational level, multivitamin (MVI) use during the first 
trimester of pregnancy, smoking, and alcohol consumption. 
 Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to 
estimate the relative risk for CLO, CL/P, and all OFCs according to the presence of 
diabetes and hypertension. Multiple logistic regression analysis was used to adjust for 
differences in maternal age, multivitamin use, and history of smoking and model the 
effect of diabetes and hypertension on CPO, CL/P, and all OFC risk. 
Results 
Table 4-1 shows the demographic characteristics of study participants. Among 
the case and control children, 60.3% (n=339) and 60.9% (n=401) respectively were 
boys. Among the case children, CL/P accounted for 66.7% (n=375) and CPO 
accounted for 33.3% (n=187) of cases. Maternal age, mean BMI, and alcohol drinking 
three months prior to pregnancy were not significantly different between mothers of 
cases and controls. Maternal smoking three months prior to pregnancy was 
significantly higher among mothers of cases (15.5%; n=85) than controls (10.0%; 
n=64). Maternal use of MVI was not statistically different between cases (33.8%; 
n=186) and controls (29.9%; n=192). Maternal education was significantly different 
among mothers of cases and controls (p-value=0.017), with a higher percent of 
mothers of controls holding a college degree (31.1%; n=200) or completed some 
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college (44.2%; n=248) compared to mothers of cases (27.5%; n=151 and 40.4%; 
n=222), respectively. Mothers of cases were more frequent to be high school graduate 
or less (32.2%; n=177) compared to mothers of controls (24.7%; n=159).  
The prevalence of maternal GDM and hypertension was significantly higher 
(p-value=0.004) among mothers of cases (5.2%; n=29 and 3.20%; n=18) than controls 
(2.1%; n=14 and 0.9%; n=6), respectively. GDM was also associated with the higher 
BMI value (p-value=0.004), but not with older maternal age (p-value=0.134). 
Maternal hypertension, however, was not significantly associated with maternal BMI 
at conception (p-value=0.088), while appeared more frequent among mothers with 
older age (p-value=0.042). Maternal GDM and hypertension were not associated with 
maternal smoking (p-value=0.383 and 0.459), MVI use (p-value=0.941 and 0.321), or 
education level (p-value=0.752 and 0.677), respectively. 
Table 4-2 illustrates the crude and adjusted Odds Ratios (aORs) for GDM on 
isolated, non-isolated OFC subtypes and both types combined. GDM appears to 
increase the risk for isolated CPO (aOR=3.36 [95% CI 1.28-8.81]), CL/P (aOR=2.49 
[95% CI 1.15-5.36]), and all isolated clefts (aOR=2.63 [95% CI 1.30-5.34]); non-
isolated CPO (aOR=3.65 [1.12-11.86]) and all non-isolated OFC (aOR=2.66 [1.02-
6.97]), but not for non-isolated CL/P (aOR=2.12 [0.57-7.87]). Overall, GDM 
increased the risk for isolated and non-isolated CPO (aOR=3.42 [95% CI 1.48-7.91]), 
CL/P (aOR=2.33 [95% CI 1.11-4.87]), and all OFCs (aOR=2.58 [95% CI 1.31-5.06]). 
Table 4-3 illustrates the crude and aORs for maternal hypertension on isolated, 
non-isolated, and both isolated and non-isolated OFC types and subtypes. Maternal 
hypertension increases the risk for non-isolated CPO (aOR=5.76 [95% CI 1.35-
24.59]), CL/P (aOR=7.87 [95% CI 2.21-27.94]), and all non-isolated OFCs 
(aOR=6.56 [95% CI 2.18-19.77]); and all CPO (aOR=3.78 [95% CI 1.18-12.07]),  
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Mean Maternal Age + standard deviation (SD) 26.2+ (5.3) 26.3+ (5.3) 26.8+ (5.9) 26.5 + (5.7) 
Mean BMI+ (SD) 24.3+ (5.4) 25.2+ (11.7) 25.1+ (12.9) 25.1+ (12.1) 
Pre-existing Diabetes (%) 2 (0.3) 1 (0.3) 0 (0.0) 1 (0.2) 
Gestational Diabetes Mellitus (%) 14 (2.1) 18 (4.8) 11 (5.9) 29 (5.2) 
Hypertension (%) 6 (0.9) 12 (3.2) 6 (3.2) 18 (3.20) 
Gestational Diabetes Mellitus and Hypertension Combined (%) 1 (0.2) 4 (1.1) 2 (1.1) 6 (1.1) 
Average month of Diagnosis of GDM + (SD) 6.2+ (1.2) 5.3+ (1.8) 5.7 + (2.0) 5.4 + (1.8) 
Maternal Smoking 3-Months Prior to Pregnancy (%) 64 (10.0) 58 (15.7) 27 (15.0) 85 (15.5) 
Maternal Alcohol Consumption 3-Months Prior to Pregnancy (%) 145 (22.6) 100 (27.0) 40 (22.2) 140 (25.5) 
Supplement use during first trimester of pregnancy (%) 192 (29.9) 118 (31.9) 68 (37.8) 186 (33.8) 
College Graduate (%) 200 (31.1) 92 (24.9) 59 (32.8) 151 (27.5) 
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Table 4-2. Risk of Orofacial Clefts by Maternal Gestational Diabetes Mellitus by 
Cleft Types 
 
Cleft Group Odds Ratios and 95% Confidence Intervals by Cleft Subtype 
CL/P1 CPO2 CL/P and CPO 
Isolated Crude  2.36 [1.13-4.96] 2.78 [1.10-7.03] 2.48 [1.26-4.90] 
Adjusted3 2.49 [1.15-5.36] 3.36 [1.28-8.81] 2.63 [1.30-5.34] 
Non-Isolated Crude 2.12 [0.60-7.58] 3.07 [0.98-9.61] 2.56 [1.01-6.46] 
Adjusted3 2.12 [0.57-7.87] 3.65 [1.12-11.86] 2.66 [1.02-6.97] 
Isolated and 
Non-Isolated 
Crude 2.32 [1.14-4.72] 2.88 [1.28-6.44] 2.50 [1.31-4.79] 
Adjusted3 2.33 [1.11-4.87] 3.42 [1.48-7.91] 2.58 [1.31-5.06] 
 
1 Cleft lip, with or without cleft palate; n=15 (4.9%) isolated, 3 (4.4%) non-isolated. 
2 Cleft palate only; n= 7 (5.7%) isolated, 4 (6.3%) non-isolated. 
3 Covariate in logistic regression model include maternal age, body-mass-index, education, 
multivitamin use, and smoking. 
 
CL/P (aOR=3.50 [95% CI 1.28-9.55]), and all OFCs (aOR=3.42 [95% CI 1.34-8.74]). 
However, no effect for maternal hypertension on isolated OFCs was observed. Crude 
and adjusted ORs of Maternal GDM by maternal body weight categories (normal 
weight, overweight, and obesity) for isolated, non-isolated, and all clefts appear in 
table 4-4. Underweight category was skipped, as no participants appeared to be 
underweight with GDM. The aORs of GDM imply the increased risk for isolated 
(aOR=4.96 [1.26-19.51]), non-isolated (aOR=14.21 [2.52-80.21]), and all clefts 
(aOR=6.30 [1.71-23.21]) among obese mothers only.  
Crude and adjusted ORs of Maternal hypertension by maternal body weight 
categories (normal weight, overweight, and obesity) for isolated, non-isolated, and all 
clefts appear in table 4-5. Maternal hypertension increases the risk for non-isolated 
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Odds Ratios and 95% Confidence Intervals by Cleft Subtype 
CL/P1 CPO2 CL/P and CPO 
Isolated Crude  2.54 [0.85-7.61] 2.71 [0.67-10.98] 2.59 [0.93-7.17] 
Adjusted3 2.54 [0.84-7.73] 2.82 [0.68-11.69] 2.56 [0.91-7.15] 
Non-Isolated Crude 8.60 [2.55-28.97] 5.33 [1.30-21.83] 6.93 [2.37-20.33] 
Adjusted3 7.87 [2.21-27.94] 5.76 [1.35-24.59] 6.56 [2.18-19.77] 
Isolated and 
Non-Isolated 
Crude 3.59 [1.34-9.65] 3.59 [1.14-11.27] 3.59 [1.42-9.11] 
Adjusted3 3.50 [1.28-9.55] 3.78 [1.18-12.07] 3.42 [1.34-8.74] 
 
1 Cleft lip, with or without cleft palate; n=7 (2.3) isolated, 5 (7.4%) non-isolated. 
2 Cleft palate only; n= 3 (2.4%) isolated, 3 (4.7%). 
3 Covariate in logistic regression model include maternal age, body-mass-index, education, 
multivitamin use, and smoking. 
 
 
Table 4-4. Risk of Orofacial Clefts by Maternal Gestational Diabetes Mellitus by 











Normal weight2  Crude  1.64 [0.57-4.73] 0.71 [0.09-5.84] 1.41 [0.51-3.94] 
Adjusted5 1.78 [0.57-5.53] 0.72 [0.08-6.52] 1.46 [0.48-4.39] 
Overweight3  
 
Crude  1.31 [0.32-5.37] 1.69 [0.18-15.87] 1.37 [0.36-5.23] 
Adjusted5 1.38 [0.32-5.93] 1.73 [0.17-17.61] 1.36 [0.34-5.36] 
Obesity4 
 
Crude  5.73 [1.50-21.87] 8.78 [1.89-40.70] 6.48 [1.79-23.38] 
Adjusted5 4.96 [1.26-19.51] 14.21 [2.52-80.21] 6.30 [1.71-23.21] 
 
1Data for underweight mothers not included as it was too sparse for analysis. 
2 BMI >18.5, < 25; n=7 isolated, 1 non-isolated clefts. 
3BMI  >25, <30; n=4 isolated, 1 non-isolated clefts. 
4BMI  >30; n=10 isolated, 5 non-isolated clefts. 
5Covariates in logistic regression model include maternal age, body-mass-index, education, 
multivitamin use, and smoking. 
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Table 4-5. Risk of Orofacial Clefts by Maternal Hypertension by Cleft Types 





























4.16 [0.78-22.04] 2.24 [0.19-25.80]  
 
3.63 [0.72-18.37] 




Adjusted5 0.81 [0.13-5.19] 5.11 [0.66-39.64]  
 
1.41 [0.29-6.88] 








1Data for underweight mothers not included as it was too sparse for analysis. 
1 BMI >18.5, < 25; n=5 isolated, 1 non-isolated clefts. 
2BMI  >25, <30; n=2 isolated, 2 non-isolated clefts. 
3BMI  >30; n=3 isolated, 4 non-isolated clefts. 
4Covariates in logistic regression model include maternal age, body-mass-index, education, 
multivitamin use, and smoking. 
 
Discussion 
This study provides evidence that maternal GDM increases the risk of having 
a child with isolated CPO, CL/P, and all isolated clefts; all CPO, CL/P, and all clefts; 
and non-isolated CPO and all non-isolated OFCs significantly. Maternal hypertension 
increases the risk for non-isolated and all CPO, CL/P, and all non-isolated and all 
OFCs significantly, but not for isolated OFCs.   
An association between maternal GDM by obesity and increased risk of 
isolated, multiple, and isolated and multiple clefts combined found to be statistically 
significant, while maternal hypertension by obesity increases the risk for non-isolated 
OFCs only. 
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The present study was designed to test maternal GDM and hypertension 
hypotheses in relation to OFCs.  High quality data were available on several 
conceptually relevant covariates to control for potential confounding. Statistical 
analyses were conducted for isolated, multiple, and isolated and multiple cleft groups 
combined and cleft subtypes (CPO, CL/P, and all clefts). The effects of maternal 
GDM and hypertension and maternal BMI categories on the risk of OFC were all 
evaluated. Although DM has been reported by previous studies to be correlated with 
the risk of congenital birth defects 23, 24, and some reported to have an effect on 
increasing the risk of OFC 25, 26, studies of the association between maternal GDM 
and OFC are limited. Similarly, studies of the association between maternal 
hypertension and OFC are limited. 
We also conducted a pooled analysis using individual data on GDM and 
hypertension and potential confounding factors (age, smoking three months prior to 
pregnancy, multivitamin use, education level, and BMI categories). The risk of 
orofacial clefting by maternal GDM and hypertension by maternal BMI categories 
was also evaluated.   
The presence of GDM and hypertension were determined based on maternal 
self-reports of diagnosed GDM that were similar to approaches used in previous 
population-based case-control studies of birth defects 27, 28. Hypertension status was 
also determined based on self-reports. Self-reported GDM may lead to 
misclassification as some women who reported having no DM may have had 
undiagnosed type-2 DM. However, there is no reason to believe that the subsequent 
misclassification of GDM status occurred differently for case and control mothers in 
this study, so the net effect was probably of an attenuation of associations of diabetes 
mellitus with OFC birth defects. 
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Other potential limitations of this study include the use of self-reported pre-
gestational weight and height and the possibility of recall bias for these variables. 
Data on exposures to smoking, and multivitamin intake were limited to dichotomous 
exposure levels, thus residual confounding related to these factors is a possibility. As 
in all case-control studies, recall bias is a concern.  
In the present study, a positive association was found between maternal GDM 
and OFCs in the offspring. Navarrete et al. indicated a definitive relation between a 
maternal glucose metabolic disorder and congenital malformations 12. Several other 
studies reported an increased risk for having newborns with OFCs in diabetic mothers 
compared to non-diabetic mothers 26, 29-31. Although GDM has been also reported by 
previous studies to increase the risk for congenital birth defects 27, 32, 33, including 
OFC 2, studies of the association between GDM and OFC are limited. In our study, 
we found a significant positive association between GDM and isolated, non-isolated, 
and all clefts.  
Hypertension has been reported to be associated with congenital 
malformations 4, while Lebby et al. indicated no effect of the presence or absence of 
hypertension on OFC risk 5. In fact, there is a lack of published studies examining the 
association between maternal hypertension and the risk of OFC. In the present study, 
we found an increased risk of non-isolated and all CPO, CL/P, all clefts. It is possible 
that hypertension during pregnancy alters the perfusion in the placenta, causing 
urogenital malformations. However, the exact teratogenic effect of hypertension is 
still unknown 34.  
A case-control study reported an increased risk of isolated and multiple birth 
defects by maternal GDM in the presence of maternal obesity after adjusting for 
maternal BMI, age, race/ethnicity, entry into prenatal care, study center, and 
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household income (aOR=1.42 [95% CI 1.17-1.73] and 1.50 [95% CI 1.13-2.00], 
respectively) 2. Similarly, our results show a higher risk of GDM for isolated 
(aOR=4.473 [95% CI 1.13-17.76]), non-isolated (aOR=16.35 [95% CI 2.71-98.62]), 
and all clefts (aOR=6.07 [95% CI 1.64-22.47]) among obese mothers, while maternal 
hypertension increased the risk for non-isolated OFC only among obese mothers 
(aOR=22.21 [95% CI 2.22-334.23]). 
While maternal GDM appears to be associated with cleft risk, pregnant 
mothers are not usually tested for hyperglycemia until 26-28 weeks of gestation, after 
formation of the lip and palate. Thus, we highlight the importance of early screening 
of all pregnant women for hyperglycemia at the time of conception. This may 
alleviate the risk of GDM and reduce the prevalence of OFC associated with GDM. 
Maternal hypertension is associated with the risk of OFC. However, studies are 
limited. Further research on the relationship between maternal hypertension, GDM 
and DM, and other metabolic syndrome factors might be warranted. 
Our findings expand on the body of literature of OFC among infants of 
women with GDM or hypertension. Given that both maternal GDM and hypertension 
were associated with an increased risk of OFCs, both CL/P and CPO, the importance 
of identifying and implementing effective detection, control, and prevention strategies 
for metabolic abnormalities, including maternal GDM and hypertension, among 
women of childbearing age is a necessity. 
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CHAPTER 5 
THE ASSOCIATION BETWEEN MATERNAL DIABETES AND OROFACIAL 
CLEFTS IN AN INTERNATIONAL CONSORTIUM OF  
CASE-CONTROL STUDIES1 
Abstract 
Objective: To evaluate whether maternal diabetes mellitus (DM) is independently 
associated with risk of orofacial clefts (OFCs).  
Methods: Pooled analyses of population-based case–control studies from a unique 
and large international consortium including Utah, Iowa, Norway (two studies 1996-
2001 and 2000-2009, Denmark, and the U.S. National Birth Defects Prevention Study 
was conducted. Subjects included mothers of 5,280 infants with OFCs and 11,461 
controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to 
estimate the relative risk for cleft subtypes associated with diabetes. Multiple logistic 
regression analysis was used to adjust for the potential confounding effects of 
maternal age, multivitamin use, maternal body-mass-index (BMI) categories, and 
history of smoking. 
Results: Maternal DM was associated with an increased risk of all types of OFCs 
after adjustment for maternal age, multivitamin use, smoking during the first trimester 
of pregnancy, and BMI. The estimated relative risk of DM for isolated OFCs was 1.33 
[95% CI 1.14-1.54] and was slightly higher for multiple OFCs (aOR=1.86 [95% CI 
1.44-2.40]). No excess risk was observed among diabetic mothers with normal body 
weight. However, diabetic mothers who were also overweight or obese had an 
increased risk for having children with isolated, multiple, and isolated and multiple 
                                                        
1 Coauthored by Hebah A. Kutbi and Ronald G. Munger 
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OFC groups combined (aOR=1.33 [95% CI 1.02-1.73], 2.61 [95% CI 1.71-3.97], and 
1.52 [95% CI 1.19-1.93]), respectively. We also found an elevated risk of OFCs 
among mothers with diabetes who were underweight (aOR=2.63 [95% CI 1.26-5.49]. 
Conclusions: Maternal DM was significantly associated with an elevated risk of all 
types of OFCs. Mothers of normal bodyweight however had no increased risk of 
OFCs if they were diabetic; the elevated risk among diabetics only occurred among 
underweight, overweight, and obese mothers. Further studies are needed to identify 
diabetes related pathways leading to the increased risk of OFCs and to understand 
how this risk is modified by risk factors related to both underweight and overweight. 
Our findings also highlight the need to assess all mothers for hyperglycemia and other 
metabolic abnormalities in the periconceptional period to reduce the risk of OFC in 
their offspring. 
Introduction 
Maternal diabetes mellitus (DM) has been implicated in several studies as a 
possible etiological factor of various infant congenital malformations 1-3. Orofacial 
clefts (OFCs) are among the most frequent congenital birth defects 4. In 2006, Centers 
for Disease Control and Prevention (CDC) reported that from 1999 through 2001, 
nearly 4,209 infants each year in the United States are born with OFCs 5. These 
estimates have been increased in 2010 to 4,437 live births per year 6. Several studies 
suggest that maternal diabetes or the underlying metabolic abnormalities known as the 
metabolic syndrome may be involved in the pathogenesis of cleft lip and cleft palate 7-
9. However, further studies are needed for a more complete understanding of the 
etiology of this disorder 10. 
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DM is a group of metabolic diseases resulting from defects in insulin 
secretion, insulin action, or both, and characterized by chronic hyperglycemia with 
disturbances of carbohydrate, fat and protein metabolism. Three main types of 
diabetes have been defined: type-1, type-2, and GDM 11. Type-1 diabetes mellitus or 
insulin-dependent diabetes mellitus (IDDM) is partly inherited and then triggered by 
certain infections. It results from a T-cell mediated autoimmune destruction of the 
pancreatic beta cells in genetically predisposed individuals 12. Type-2 diabetes or non-
insulin-dependent diabetes mellitus (NIDDM) is due primarily to lifestyle factors and 
genetics 13. GDM is a condition in which women without previously undiagnosed 
diabetes exhibit high blood glucose levels (particularly during third trimester of 
pregnancy) when their bodies do not secrete excess insulin required during pregnancy 
14. 
Type-1 and type-2 are both conditions that can be treated but not cured 15. 
GDM may increase the risk for developing diabetes when they are not pregnant 16. It 
has been predicted that mothers who develop GDM later in pregnancy may also have 
had undetected metabolic problems earlier in the pregnancy 17. Hence, diet, exercise, 
and use of appropriate medications to keep blood sugar levels as close to normal 
"euglycemia" can be achieved 15.  
In 1970, Navarrete et al. found an association between congenital 
malformation of infants and the development of diabetes in their mothers later in life 
and suggested research into the early phases of diabetic state in mothers pregnant of  
malformed infants 18. Several studies reported an increased risk for having newborns 
with OFCs in diabetic mothers compared to non-diabetic mothers 19-22 with a higher 
statistical significant rate of cleft palate only (CPO) 20. 
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Thus, investigation of DM may provide useful clues regarding birth defects 
associations 23. We assessed the relationship between maternal DM and the risk of 
OFC birth defects. DM is hypothesized to cause OFCs via metabolic abnormalities 
that affect fetal development. This hypothesis was examined in analyses of data from 
the international consortium of case-control studies from Utah, Iowa, Norway, 
Denmark, and the U.S. National Birth Defects Prevention Study. 
Materials and Methods 
This study is a combined, unique, and large international consortium of case-
control studies from the U.S. (two separate studies from Iowa, Utah, and the U.S. 
National Birth Defects and Prevention Study-NBDPS), Denmark, and Norway. The 
combined sample includes 16,741 women including 5,280 mothers of children with 
OFCs and 11,461 mothers of unaffected children. Data were available on the presence 
of DM, pre-pregnancy maternal weight and height, in addition to other perinatal and 
demographic factors, which are used as covariates to control for potential 
confounding. Body-mass-index (BMI) was computed as weight kilograms 
(kgs)/height (m2) and used to define body weight categories as underweight 
(BMI<18.5 kg/ m2), normal weight (18.5 <25 kg/ m2), overweight (25 <30 kg/ m2) 
and obesity (≥30 kg/ m2). Studies included in this current study are as follows:  
(1) Iowa Case-Control Sample: The Iowa Registry of Congenital and Inherited 
Disorders (IRCID) case-control sample consists of about 287 cases with CL/P and 
302 controls born between 1987 through 1996. The control sample was randomly 
selected from all unaffected live births and matched to the affected sample by birth 
month, year and gender. Data on risk behaviors, socioeconomic characteristics and 
other relevant data, were obtained through telephone-based interviews and self-
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administered forms sent by mail 24.  
(2) Utah Study: A state-wide case-control study of clefts was conducted in 
Utah during 1995 to 2004 in collaboration with the Utah Birth Defects Network 
(UBDN) involves 561 cases with CL/P and 660 randomly selected unaffected births 
(from birth certificates) matched cases by month, year of birth, and gender of the 
child.  The UBDN staff members attempted to contact potential case and control 
mothers by mail to obtain consent for release of their names to USU investigators. 
Address updates were sought using available Internet services. If no mailing address 
was available, attempts were made to locate the mothers in person by field tracing that 
included visits to the last known home address and inquiries with neighbors. The 
UBDN later joined the National Birth Defects Prevention Study (NBDPS) described 
below. A detailed description of data collection is provided elsewhere 25.  
(3) National Birth Defects Population Studies: NBDPS samples with CL/P and 
control samples multiple participating States were included. These include Arkansas, 
California, Georgia, Massachusetts, New Jersey, New York, North Carolina, Iowa, 
Texas and Utah. NBDPS sample provided 3491 CL/P cases and 8357 control 
mothers, matched by State and birth year to the CL/P sample 26.  
(4) Danish Study: The data were extracted from the Danish National Birth 
Cohort study between 1997 and 2003 and involved a sample of 828 mothers of 
affected cases with CL/P and 156 randomly selected mothers of unaffected births. The 
women were typically enrolled in the study at the first visit to general practitioners 
(usually in the first trimester). Participated mothers were interviewed about a broad 
range of health related information, such as health and risk behaviors, potential fetal 
risk factors, socioeconomic and other relevant characteristics. Further follow-up with 
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mothers of children with congenital anomalies was conducted after birth and until the 
child is 18 months of age.  
(5) Norway Facial Cleft Study: The Norway Facial Clefts Study, or Norway 
Case-Control study (Norway CC), is a population survey of infants born with CL/P in 
Norway in 1996 through 2001. Data included 570 cases and their parents and a 
randomly selected control sample of 736 infants born without birth defects in the 
same period 27. Extensive data on maternal behaviors and household factors and 
socioeconomics were available. The data collection is described elsewhere 28.  
(6) Norway National Mother and Child Cohort Study: The Norwegian Mother and 
Child Cohort Study (MoBa), conducted by the Norwegian Institute of Public Health 
(NIPH, Oslo, Norway), is a cohort consisting of pregnancies recruited beginning in 
1999 to 2008 29. Identified were 164 cases of CL/P and 551 control mother of which 
were randomly selected with matching to the case sample by year and state of birth.  
Data on maternal health behaviors, demographic and socioeconomic characteristics, 
health problems and food behaviors were obtained during pregnancy between weeks 
15 and 30 (data on risk and health behaviors was collected between 15 and 18 weeks). 
The study also involved follow-up interviews with the mother and child until the child 
is three years.  
SPSS statistical analysis version 20.0 was used to describe the characteristics 
of study population. Descriptive analysis was conducted in SPSS to examine the 
association between maternal DM and other factors, such as maternal age, history of 
smoking (three months prior to conception), multivitamin use during the 
periconceptional period, and education level (college graduate, high school graduate 
only, and less than high school graduate) and alcohol consumption. 
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 Simple Chi-square analysis of contingency tables for categorical analysis was 
used to examine the association between each independent variable and selected 
covariates, such as maternal educational level, multivitamin use during the first 
trimester of pregnancy, smoking, and alcohol consumption. 
 Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to 
estimate the relative risk for cleft lip only (CLO), cleft lip with or without cleft palate 
(CL/P), cleft lip and cleft palate (CLP), cleft palate only (CPO), and all orofacial 
clefts (OFCs) according to the presence of diabetes. Multiple logistic regression 
analysis was used to adjust for differences in maternal age, multivitamin use, maternal 
BMI categories, and history of smoking, and model the effect of diabetes on OFC 
risk. 
Results 
Table 5-1 summarizes the types of clefts, the numbers, and the sources of 
samples. Among the case children, CL accounted for 23.09% (n=1,219), CL/P 
accounted for 65.36% (n=3,451), and CP accounted for 34.68% (n=1,831) of cases. 
Within CL cases, 1,107 (90.8%) and 112 (9.2%) children cases were reported to have 
isolated and multiple birth defects, respectively. Isolated CL/P accounted for 2,976 
(86.2%) cases and 475 (13.8%) cases had multiple CL/P. Within CP cases, 1345 




                                                                                                                                                                                                                                                                                                                                                                                   
121 




Site and Birth years 
Number of study participants by cleft type 
Controls CLO CPL CPO All OFCs 
Iowa, USA 
(1987-1991) 
302 56 111 120 287 
Utah, USA 
(1995-2004) 
660 142 232 187 561 
U.S. National Birth Defects Prevention Study 
(1997-2008) 
8357 792 1491 1208 3491 
Danish National Birth Cohort 
(1998-2001) 
828 58 72 57 187 
Norway Case-Control Study 
(1996-2001) 
763 140 234 196 570 
Norway Mother-Baby (MoBa) Study 
(2000-2009) 
551 31 94 63 184 
Total sample 11461 1219 2234 1831 5280 
 
 
Table 5-2. Number of Orofacial Cleft Cases by Cleft Type; International 
Consortium of Orofacial Cleft Case-Control Study  
 
Cleft Type Cleft Lip Only Cleft Lip with or 
without Cleft Palate 
Cleft Palate Only 
Isolated Clefts 1107 2976 1345 
Multiple Clefts 112 475 486 
All Clefts 1219 3451 1831 
 
Demographic characteristics of the sample appear in table 5-3. The mean ages 
of mothers of cases and controls were significantly different at Iowa (p-value=0.002) 
and NBDPS (p-value<0.001) study sites. Smoking during the first trimester of 
pregnancy was common and associated significantly with the risk of OFCs among 
Utah (p-value=0.002), Danish (p-value=0.035), Norway (p-value<0.01) and NBDPS 
studies (p-value<0.05). Maternal BMIs of mothers of cases and controls were 
significantly different among NBDPS sample group, but not at other study sites. Use 
of alcohol by the mother during the first trimester of pregnancy was significantly 
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more frequent (p-value=0.004) among the case versus control mothers in Norway 
study; no significant associations were seen in the other studies. Maternal caffeine use 
during the first trimester was associated significantly with the risk of OFCs in MoBa 
study only (p-value=0.023). Maternal employment was significantly associated with 
the risk of OFC among Norway sample (p-value=0.019) and NBDPS sample (p-
value=0.018), but was not among any other study sites. Maternal multivitamin (MVI) 
use was significantly associated with the risk of OFC within NBDPS (p-value=0.024) 
sample only. Maternal education was associated with the risk of OFC within Norway 
sample (p-value=0.040) and NBDPS samples (p-value <0.001). 
The prevalence of DM was 5.3% among control mothers and 7.2% among 
case mothers. The prevalence of DM varied considerably across study sites and 
generally higher in the U.S. sites compared to the European sites. In subgroup 
analyses, maternal DM was significantly associated with the risk of OFCs in the  Utah 
and NBDPS samples, where higher percent of cases among diabetic mothers were 
observed (5.7% and 9.3%) compared to controls (2.6% and 6.6%), respectively. 
Maternal age of mothers of cases and controls were significantly different among 
Iowa (p-value=0.004) and NBDPS (p-value<0.001) study sites. Maternal smoking 
during the first 3 months of pregnancy differed between case and control mothers in 
Utah (p-value=0.006), Norway (p-value=0.016), and Iowa (p-value=0.026). Maternal 
BMIs of mothers of cases and controls were significantly different among Utah (p-
value<0.001), Norway (p-value=0.021), and NBDPS (p-value<0.001). Maternal 
alcohol and caffeine use were not significantly associated with maternal DM of cases 
and controls at any study site. Maternal education level was significantly associated 
with maternal DM in NBDPS sample, but not at other study sites.
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Utah Norway CC Moba Iowa CC NBDPS Danish  
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
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Smoker % 13.5 8 41.6 31.8 27.6 23.8 25.1 22.2 21.2 16.2 6.2 21.9 
Alcohol use in 1st trimester % 7.5 6.4 38.1 30.5 12.7 14 34.5 34.8 22.9 22.5 43.3 42.6 
Maternal employment % 88.1 85.6 80.2 85.1 78.6 79.2 N/A N/A 69.5 71.7 NA NA 
Maternal caffeine use in first  
Trimester % 
98.6 98.3 89.6 89.8 86.2 92.4 85.0 83.8 70.9 69.8 95 92.4 
Multivitamin use % 75.8 75.6 37.2 40.6 70.7 74.6 63.6 71.1 82.2 83.9 56.2 61.3 
Education <  High school % 8.0 6.5 16.1 11.4 5.7 2.6 9.8 7.6 19.9 17.3 N/A N/A 
College Graduate % 26.7 30.5 39.6 40.9 62.7 62.4 18.1 22.5 26 31.6 N/A N/A 
High School graduate % 65.2 63 44.2 47.7 31.6 34.9 72.1 69.9 54.2 51.1 N/A N/A 
Male % 59.2 60.6 60.3 53.3 58.2 55.2 53.8 54 58.6 50.9 N/A N/A 
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Because crude and adjusted ORs (aOR) were very similar, only aORs are 
presented. The estimated relative risk for having offspring with isolated clefts, 
multiple clefts, and all clefts increased significantly with maternal DM (aOR=1.33 [CI 
95% 1.14-1.55], aOR=1.86 [CI 95% 1.44-2.40], and aOR=1.41 [CI 95% 1.23-1.62]), 
respectively (table 5-4). Maternal DM was associated with significantly increased risk 
for having CL, CL/P, and CP among the isolated OFC, with aORs ranging from 1.29 
to 1.39; among multiple CL/P and CPO, with aORs of 1.74 [CI 95% 1.22-2.49] and 
2.00 [CI 95% 1.42-2.82] respectively, and among isolated and multiple cleft groups 
combined, with aORs ranging from 1.35 to 1.52. 
 
Table 5-4. Adjusted Odds Ratios (aORs)1 and 95 Percent Confidence Intervals 
(CIs) of Orofacial Cleft Types and Subtypes by Maternal DM 
 
Cleft Types Cleft Lip Only 
Cleft Lip with or 
without Cleft 
Palate 
Cleft Palate Only All Clefts 
Isolated Clefts 1.37 [1.06-1.79] 1.29 [1.09-1.55] 1.40 [1.11-1.75] 1.33 [1.14-1.55] 




1.35 [1.05-1.74] 1.35 [1.15-1.60] 1.53 [1.25-1.86] 1.41 [1.23-1.62] 
 
1 Covariates in logistic regression models include study site, maternal age, education levels, 
multivitamin use, maternal BMI categories, and history of smoking
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Statistical analyses were used to evaluate the possibility of effect modification 
of the association between maternal DM and OFCs by maternal weight categories 
(table 5-5). In a multiple logistic regression analysis that controlled for maternal age 
groups, maternal smoking during the first trimester of pregnancy, multivitamin use, 
and education (college graduate vs. not college graduate) shown in table 9, the 
estimated relative risk for having isolated and all clefts increased significantly with 
maternal underweight (1.0 [reference]; OR= 2.76 [95% CI 1.29-5.93] and 2.63 [95% 
CI 1.26-5.49]), respectively. Maternal overweight and obesity increased the risk of 
having isolated, multiple, and isolated and multiple clefts combined significantly, 
with aOR ranging from 1.33 to 2.61. DM was not associated with OFCs among 
normal weight mothers. 
 
Table 5-5. Adjusted Odds Ratios (aORs)1 and 95 Percent Confidence Intervals 













BMI  <18.5 
2.76 [1.29-5.93] 2.13 [0.56-8.05] 2.63 [1.26-5.49] 
Normal weight  
BMI >18.5, < 25 
1.11 [0.85-1.44] 1.13 [0.67-1.92] 1.11 [0.87-1.43] 
Overweight  
BMI  >25, <30 
1.45 [1.10-1.91] 1.81 [1.13-2.91] 1.51 [1.17-1.96] 
Obese  
BMI  >30 
1.33 [1.02-1.73] 2.61 [1.71-3.97] 1.52 [1.19-1.93] 
 
1 Covariates in logistic regression models include study site, maternal age, education levels, 
multivitamin use, and history of smoking.
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The estimated relative risk of DM with maternal underweight for having 
isolated and all CPO (OR=4.26 [1.58-11.48] and 4.00 [1.59-10.04]) respectively 
appeared to be higher than in the other body weight groups. Maternal overweight 
increased the risk for isolated, multiple, and all CL/P in addition to isolated and all 
CPO. Maternal obesity increased the risk for isolated and all CLO; isolated, multiple, 
and all CL/P; and multiple and all CPO. Diabetic normal weight mothers had no 
increased risk for any OFC type (table 5-6).  
Table 5-7 shows the aORs of OFCs types and subtypes by maternal DM 
stratified by maternal periconceptional multivitamin (MVI) use vs. non-multivitamin 
use. The results demonstrate a slightly decreased risk of isolated  (aOR=1.30 [95% CI 
1.01-1.54]) and isolated and non-isolated OFC groups combined (aOR=1.35 [95% CI 
1.15-1.57]) among MVI users compared to non-MVI users (aORs=1.48 [95% CI 
1.05-2.09] and 1.72 [95% CI 1.26-2.35], respectively). However, the effect of MVI 
use in attenuating the risk of OFCs among mothers with DM appeared to be stronger 
for OFCs with multiple birth defects (aOR=1.62 [95% CI 1.19-2.20]) compared to 
non-multivitamin users (aOR=2.73 [95% CI 1.67-4.46]).
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Table 5-6. Adjusted Odds Ratios (aORs)1 and 95 Percent Confidence Intervals (CIs) of Orofacial Cleft Types and Subtypes 






Cleft Lip Only Cleft Lip with or 
without Cleft Palate 








2.01 [0.53-7.55] 2.16 [0.89-5.20] 4.26 [1.58-11.48] 2.76 [1.29-5.93] 
Normal Weight  
BMI>18.5, <25 
0.92 [0.55-1.52] 1.01 [0.74-1.39] 1.29 [0.87-1.91] 1.105 [0.85-1.44] 
Overweight 
BMI>25, <30 
1.58 [0.99-2.53] 1.39 [1.00-1.92] 1.53 [1.01-2.32] 1.45 [1.10-1.91] 
Obesity 
BMI >30 








4.56 [0.47-44.33] 1.34 [0.17-10.81] 3.35 [0.66-16.86] 2.13 [0.56-8.05] 
Normal Weight  
BMI>18.5, <25 
0.61 [0.08-4.44] 0.98 [0.45-2.12] 1.27 [0.64-2.53] 1.13 [0.67-1.92] 
Overweight 
BMI>25, <30 
0.85 [0.11-6.48] 2.09 [1.10-3.96] 1.60 [0.82-3.09] 1.81 [1.13-2.91] 
Obesity 
BMI >30 









2.37 [0.73-7.71] 2.02 [0.86-4.74] 4.00 [1.59-10.04] 2.63  [1.26-5.49] 
Normal Weight  
BMI>18.5, <25 
0.89 [0.54-1.46] 1.01 [0.75-1.37] 1.29 [0.91-1.83] 1.11 [0.865-1.43] 
Overweight 
BMI>25, <30 
1.53 [0.96-2.41] 1.47 [1.09-1.99] 1.54 [1.07-2.22] 1.51 [1.17-1.96] 
Obesity 
BMI >30 
1.64 [1.06-2.55] 1.53 [1.15-2.02] 1.53 [1.08-2.17] 1.52 [1.19-1.93] 
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Table 5-7.  Adjusted Odds Ratios (aORs) and 95% Confidence Intervals (CIs) of Orofacial Cleft Types and Subtypes by Maternal 




















Orofacial Cleft Type Cleft Lip Only Cleft Lip with or without 
Cleft Palate 
Cleft Palate Only All Clefts 
 
MVI Users 
Isolated Clefts 1.27 [0.94-1.72] 1.24 [1.02-1.51] 1.41 [1.10-1.82] 1.30 [1.10-1.54] 
Multiple Clefts 0.85 [0.26-2.75] 1.35 [0.86-2.13] 1.91 [1.28-2.83] 1.62 [1.19-2.20] 
Isolated and Multiple 
Clefts Combined 
1.24 [0.92-1.67] 1.25 [1.04-1.51] 1.41 [1.10-1.82] 1.34 [1.15-1.57] 
Non-MVI Users Isolated Clefts 1.89 [1.10-3.26] 1.57 [1.07-2.31] 1.30 [0.76-2.22] 1.48 [1.05-2.09] 
Multiple Clefts 1.83 [0.41-8.10] 3.20 [1.72-5.94] 2.19 [1.08-4.45] 2.73 [1.67-4.46] 
Isolated and Multiple 
Clefts Combined 
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Discussion 
This study provides evidence that maternal DM significantly increases the risk 
of having a child with OFC. An association between maternal DM among obese 
mothers and increased risk of isolated, multiple, and isolated and multiple clefts 
combined found to be statistically significant. Interestingly, the risk of maternal DM 
among underweight mothers appeared to be higher than among obese mothers in 
isolated and isolated and multiple cleft groups combined, while no excess risk was 
found among diabetic mothers with normal weight.  
This is the largest international consortium of case-control study to date with 
multiple countrywide sites in Europe and statewide sites in the US. The study is 
population-based and relatively robust against selection bias. OFC cases were drawn 
from birth defects registries. Data on potential confounders were obtained through the 
process of interviewing participants. The study was designed to use well-defined 
procedures for case definition and careful classification of OFCs and associated 
conditions by clinical specialists.   
The present study was designed to test the maternal DM hypothesis in relation 
to OFCs.  High-quality data were available on several conceptually relevant 
covariates to control for potential confounding. Statistical analyses were conducted 
for isolated, multiple, and isolated and multiple cleft groups combined and cleft 
subtypes. The effects of maternal DM and maternal BMI categories on the risk of 
OFC were all evaluated. As DM is an epidemic health problem, a modest effect of 
maternal DM can be linked to a significant burden of OFCs. We also conducted a 
pooled analysis using individual data on DM and potential confounding factors (age, 
smoking during the first trimester of pregnancy, multivitamin use, education level, 
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and BMI categories). The risk of orofacial clefting by maternal DM by maternal BMI 
categories was also evaluated.   
The presence of DM was determined based on maternal self-reports of 
diagnosed DM that were similar to approaches used in previous population-based 
case-control studies of birth defects 30, 31. This is subject to DM status 
misclassification as some women who reported having no DM may have had 
undiagnosed type-2 DM. However, there is no reason to believe that the subsequent 
misclassification of DM status occurred differently for case and control mothers in 
this study, so the net effect was probably of an attenuation of associations of diabetes 
mellitus with OFC birth defects. 
Other potential limitations of this study include the use of self-reported pre-
gestational weight and height and the possibility of recall bias for these variables. 
Data on exposures to smoking, and multivitamin intake were limited to dichotomous 
exposure levels, thus residual confounding related to these factors is a possibility. As 
in all case-control studies, recall bias is a concern.  
With the rising rates of DM 32, the current findings of the association between 
maternal DM and OFCs in the offspring is a major public health concern. Studies of 
the association between maternal DM and risk of OFCs have produced somewhat 
consistent findings for the positive effect of DM, although an inconsistency related to 
the effect on the type of cleft has been observed 19, 20, 22, 33, 34. This may be related to 
variations in population sample size, definitions of OFC subtypes, lack of 
consideration of maternal underweight, and inadequate control of potential 
confounding factors.   
In the present study, a positive association was found between maternal DM 
and OFCs in the offspring. This is similar to results reported by previous studies 19, 20, 
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22, 33, 34. However, Carinci et al., and Arteaga et al. reported a higher correlation 
between DM and isolated clefts 20, 34, while Tantbirojnet al. indicated a higher risk of 
CL/P among diabetic mothers . Our results indiated an increased risk for isolated, 
non-isolated, and both cleft groups combined when maternal DM is present, with a 
higher aOR for multiple clefts than in isolated clefts (aOR=1.86 [95%CI 1.44-2.40] 
and 1.33 [95%CI 1.14-1.55]), respectively. Yet, the aOR of isolated and non-isolated 
cleft groups combined was the highest compared to each separate group (aOR=1.41 
[95%CI 1.23-1.62]). This result is consistent with the one reported by Correa et al. in 
which the association between maternal DM and multiple defects is stronger than 
with isolated defects 2. Possible explanation for the stronger associations with 
multiple OFC includes an increased underlying susceptibility and/or exposure to a 
more adverse metabolic environment in utero. Further research is warranted to 
elucidate the basis for the variation in the ORs by OFC subtype and to identify the 
reasons for the stronger associations of DM with multiple defects. 
DM has been found in earlier studies to be associated with various birth 
defects including OFCs. The consistent finding of the associations between maternal 
DM and birth defects suggest the hypothesis that complex underlying metabolic 
disorders that are associated with DM increase the likelyhood that signal transduction 
pathways and morphogenic processes might be distrubed 35-37. 
The association of DM in the presence of obesity with OFC has been observed 
in a few other studies 8, 22, 38. Similarly, our results indicate that pregnancies of women 
who were both obese and diabetic increase the risk for having an offspring with OFC, 
with ORs ranging from 1.33 to 2.61 for isolated, multiple, and both groups combined. 
However, pregnancies of women who were underweight and diabetic also appeared to 
have a higher risk for OFC compared to obese mothers, with an estimated relative risk 
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of 2.8 [95% CI 1.29-5.93] for having offspring with isolated cleft, 2.6 [95% CI 1.26-
5.49] for any type of cleft, and 4.3 fold increased risk [95% CI 1.58-11.48] for 
isolated CPO. Rao, 1984 reported an association between maternal undernutrition and 
DM. Maternal underweight is a form of undernutrition and can be an important 
determinant of DM in an individual through a process of impairing beta cells 
progressively or by increasing the susceptibility of the individual to other genetic and 
environmental diabetogenic influence 39. Thus, mothers characterized by being lean 
can be at a similar risk for developing DM as obese individuals. However, mothers 
who are both lean and diabetic may be at an even higher risk to have an infant with 
OFC compared to obese mothers. 
Multiple CPO represented the highest risk when maternal DM is present 
(aOR= 1.98 [95% CI 1.40-2.80]). Maternal obesity combined with DM was also 
associated with a higher risk for CPO. On the other hand, women with DM and 
normal weight had no excess risk of having offspring affected by OFC. This is similar 
to the study reported by Moore et al. 8, suggesting that obesity and DM may act 
synergistically in the pathogenesis of congenital abnormalities. Maternal obesity on 
cleft palate malformation was reported to have an indirect influence of excess 
adiposity due to bioaccumulation and release of dioxins, which have been shown to 
cause cleft palate in mice 40. Both obesity and DM are indicators for metabolic 
syndrome and are also associated with conditions known as “diabesity” 32, implying a 
possible role of metabolic syndrome on palate formation in the embryo 41. 
What mechanisms could link maternal DM to OFCs in the offspring? 
Whatever the underlying mechanism behind the observed associations is, maternal 
DM appears to be associated with the risk of all types of OFC. While no excess risk 
of OFCs within diabetic normal weight mothers was found, mothers who were 
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diabetic and underweight, overweight, or obese had an increased risk for having 
inborn with any type of OFCs. Diabetic underweight mothers showed a higher risk 
than that of obese diabetic mothers to have a child with OFC. Thus, maternal DM 
combined with obesity or underweight appear to be an indirect measure of cleft risk, 
suggesting that the state of mothers being underweight does not reduce or protect 
against the risk of OFC. Further studies are needed to understand how this risk is 
modified by risk factors related to both underweight and overweight.  
DM can be caused by various environmental and genetic factors, including 
obesity, sedentary lifestyles, and overnutrition 32. Previous studies reported that even 
in the absence of maternal diabetes, obese women have been found to have an 
impaired glucose metabolism 42, which may be associated with an elevated risk for 
OFCs 8, 19, 22. Multivitamin use appeared to attenuate the risk of OFCs due to DM. 
Although OFC deformities occur within the first trimester of pregnancy, and given 
that DM is associated with an increased risk for OFC, there is only a few data on 
screening tests before 24 weeks' gestation. Therefore, further studies on appropriate 
methods for diabetes testing in the periconceptional period for all mothers, including 
underweight mothers, are recommended. 
This is the largest study to date to test the association between maternal DM 
and risk of having a newborn with an OFC. Maternal type-1 DM is significantly 
associated with the risk of OFCs. Diabetic women who are also obese have a higher 
risk to have an offspring with OFC compared to diabetic mothers with normal weight. 
Underweight mothers who are also diabetic have a doubled increased risk to have 
inborn with OFC. Multivitamin use appeared to attenuate the risk of OFCs due to 
GDM. To prevent this devastating craniofacial anomaly, our findings highlight the 
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need of obstetricians and gynecologists to assess all mothers for hyperglycemia in the 
periconceptional period to reduce the risk of OFC in their offspring.  
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CHAPTER 6 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
Summary 
The overall objective of this dissertation was to determine whether maternal 
obesity, diabetes and gestational diabetes, and maternal hypertension are 
independently associated with the risk of orofacial cleft (OFC) birth defects. OFCs are 
among the most common structural birth defects and a public health problem. There is 
a strong evidence of an etiologic role for both genetic and environmental factors. 
Environmental factors that have been associated with the risk of cleft include 
maternal smoking, multivitamin use, alcohol drinking, socioeconomic status, and 
body weight. Several studies suggest that maternal obesity, diabetes mellitus (DM), or 
the underlying metabolic abnormalities known as the metabolic syndrome, may be 
involved in the pathogenesis of cleft lip and cleft palate, and it is unclear whether this 
is true also for maternal gestational diabetes mellitus (GDM). With the rising rates of 
excess weight among pregnant women, even a modest effect of maternal obesity may 
result in excess risk of OFC. Maternal weight gain increases the risk for DM and 
hypertension. Although hypertension has been associated in a few studies with 
congenital birth defects, studies examining the risk associated with OFC are limited. 
Investigation of metabolic syndrome, with the presence of obesity, diabetes, 
hypertension, and other more serious physiologic consequences, may provide useful 
clues regarding birth defects associations. 
The results of the studies conducted in this dissertation support the roles of 
abnormal maternal weight- both underweight and obesity- and gestational diabetes 
and hypertension on increasing the risk of OFC. A pooled analysis of population-
based case–control studies conducted using the international consortium of case-
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control studies from Utah, Iowa, Norway, and the U.S. National Birth Defects 
Prevention Study confirmed the independent association between maternal obesity 
and underweight and the risk of cleft palate. The effect of maternal education level on 
the risk of OFC was also tested. Interestingly, an increased risk for cleft lip with 
palate, cleft palate only, cleft palate with or without cleft lip, and all clefts was 
observed among mothers with lower education levels, while no effect on cleft lip only 
was seen. This may suggest a possible indirect effect of maternal education level on 
cleft palate risk. Thus, maternal body weight categories association with the risk of all 
cleft palate was tested after stratifying by maternal education level. The results 
showed an increased risk for cleft palate with or without cleft lip in obese and 
underweight mothers when mothers were less educated, with a highest risk observed 
among the underweight mothers. Such effect can be related to a combination of 
maternal underweight with lifestyle with behavioral factors associated with lower 
maternal education. In some previous studies, conclusions about the association 
between maternal obesity and orofacial clefting were limited by small number of 
cases, while this study represented the largest international consortium of case-control 
study to date with multiple countrywide sites in Europe and statewide sites in the U.S.  
In a statewide case-control study of clefts conducted in Utah in collaboration 
with the Utah Birth Defects Network (UBDN), an increased risk for isolated and non-
isolated clefts was observed among mothers diagnosed with GDM; while 
hypertension increased the risk for non-isolated and the results were suggestive for 
isolated clefts. As maternal obesity has been reported to be associated with both 
maternal GDM and hypertension, the risk of isolated and non-isolated OFC was tested 
within the different maternal body weight groups. Results indicated an increased risk 
for isolated and non-isolated clefts when the GDM is present among obese mothers. 
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Hypertension appeared to increase the risk for OFCs and this seems more pronounced 
for multiple OFCs and obese mothers.  
 Lastly, the analyses of the international consortium data revealed an 
association between DM on the risk of OFCs across all types (isolated, non-isolated, 
and all clefts) and subtypes (cleft lip only, cleft lip with or without cleft palate, and 
cleft palate only). When data were stratified by maternal body weight categories, 
maternal overweight and obesity combined with the presence of DM appeared to 
increase the risk of isolated, non-isolated, and all cleft groups combined. Maternal 
underweight status with the presence of DM also increased the risk of isolated and all 
cleft groups combined and the risk appeared to be stronger compared to that of 
obesity and overweight when combined with DM. Notably, diabetic mothers with 
normal weight did not have a significant elevated risks for OFCs. 
Limitations and Future Directions 
The dissertation described here provides evidence of the roles of maternal 
obesity, DM, and GDM, and hypertension on OFC risk after adjusting for potential 
confounders. There are some limitations that must be discussed and addressed in 
future work. One limitation was the self-reported pre-gestational weight and height 
collected in the international consortium data. It is common among obese women to 
underreport their weights and overestimate their heights 1, resulting in an 
underestimation and misclassification of body-mass-index (BMI). However, even 
with the possibility of maternal underestimation of BMI, a significant increase in the 
risk of having a child with OFC birth defects was observed among the obese mothers 
and that effect could be stronger if the prevalence of obesity in the study sample was 
have accurately assessed.   
                                                                                                                                                                                                                                                                                                                                                                                   
141 
In addition to the limitations of use of self-reported pre-pregnancy weight and 
height and the possibility of recall bias, in the study examining the role of maternal 
DM on the risk of OFC, the DM was determined based on maternal self-reports of 
diagnosed DM. This is subject to DM status misclassification as some women who 
reported having no DM may have had undiagnosed DM. However, there is no reason 
to believe that the subsequent misclassification of DM status occurred differently for 
case and control mothers in this study, so the net effect was probably of an attenuation 
of associations of diabetes mellitus with OFC birth defects. 
The role of maternal GDM and hypertension was based on Utah OFC study. 
Due to the small number of participants with GDM and hypertension, the confidence 
intervals were wide. However, the detection for the increased risk even with this small 
sample size was suggestive and should encourage further research.   
Although the potential confounders in the analyses of studies in this 
dissertation were adjusted for, it is possible that residual confounding exists. To better 
understand the underlying etiology of OFCs and whether genes and environmental 
risk factors play a causal role for OFCs, future studies are needed. 
The following recommendations are also offered for related research on OFC: 
1. Given that maternal obesity, DM, and hypertension are all risk factors of 
metabolic syndrome, and appeared to have strong effects on increasing the 
risk of OFC, further studies on the exact pathophysiology of this syndrome 
may help in understanding the causal mechanisms for OFCs. 
2. Research related to other potential environmental factors and genes and how 
they interact with maternal metabolic abnormalities would be of value to help 
better understand the etiology of OFCs. 
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3. Based on the results of the dissertation, maternal underweight and obesity may 
both have severe effects on the offspring. As it is unclear whether the cause is 
related to mothers’ weight or other factors related to body composition, further 
research on the difference between obese, but metabolically healthy 
individuals and lean, but metabolically unhealthy people may justify why 
some people present to have higher risk for metabolic disorders than others, 
independently of body weight. 
Recommendations for Practitioners 
The following recommendations are offered for related research on OFC: 
1. Based on the results of this dissertation, it is recommended to modify the 
guidelines of maternal screening for abnormal glucose tolerance to be 
performed in pre-conceptional and early prenatal visits of all women, 
highlighting that underweight mothers should be also tested for as they may 
have a higher risk for having offspring with congenital anomalies.   
2. Given that obesity, DM, and hypertension are modifiable diseases and can be 
prevented through the application of healthy behaviors, it is recommended to 
inform and educate mothers planning for pregnancy on distinct practices to 
remain healthy and avoid pregnancy complications.  
Conclusions 
In conclusion, this dissertation presents additional insight into the possible 
etiologies associated with OFCs. The findings indicate that maternal obesity and 
underweight increase the risk of cleft palate in the offspring significantly; the risk 
increases further among mothers with lower education levels, while higher maternal 
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education levels protect against the effect of maternal underweight and obesity against 
the risk of OFCs. Additionally, the results support the hypotheses that maternal GDM 
and hypertension are independently associated with the risk of OFCs. Maternal DM 
increases the risk of all types (isolated, non-isolated, and all clefts) and subtypes (cleft 
lip only, cleft lip with or without cleft palate, and cleft palate only) of OFCs; and the 
risk increases further when maternal obesity is present among diabetic mothers. 
Normal weight mothers who were diabetic had no increased risk. 
The findings demonstrated here can pose an important role for guiding further 
studies to identify risk factors associated with OFCs. Additional studies will be 
helpful in elucidating the pathophysiology behind these associations with OFCs.  
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